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ABSTRACT 
Systematic chromosome-wide search for novel fetal 
epigenetic markers for detection of fetal trisomy 13 
Cell-free fetal DNA was found to be present in maternal plasma under a high 
maternal DNA background. Specific detection of fetal DNA in maternal plasma 
could be facilitated by fetal-specific DNA methylation patterns, and therefore, could 
enable the noninvasive detection of fetal chromosomal aneuploidies. 
Recently, a novel method, namely epigenetic-genetic (EGG) chromosome 
dosage approach, has been developed for the noninvasive detection of trisomy 21. In 
trisomy 21 pregnancies, an additional dose of fetal chromosome 21 is released from 
the placenta into the maternal circulation. Thus, noninvasive prenatal detection of 
trisomy 21 could be achieved by the relative chromosome dosage comparison 
between a fetal-specific epigenetic marker on chromosome 21 (the putative promoter 
of holocarboxylase synthetase, HLCS) and a fetal-specific genetic marker on another 
non-trisomic reference chromosome in maternal plasma. The detection of the fetal 
epigenetic marker in maternal plasma has been achieved by using 
methylation-sensitive restriction endonucleases (MSREs), which remove most of the 
i 
unmethylated maternal HLCS in the maternal plasma, while leaving the fetal-derived 
methylated sequences intact for detection. In this thesis, I hypothesized that certain 
regions on chromosome 13 might be differentially methylated between fetal and 
maternal DNA in maternal plasma. I also hypothesized that such regions may be 
exploited for the application of the EGG approach for the noninvasive prenatal 
detection of fetal trisomy 13，which is the third commonest fetal trisomy. 
To apply the EGG approach, we need a fetal epigenetic marker, which is 
hypermethylated in the placenta (the predominant source of fetal DNA in maternal 
plasma) and unmethylated in maternal blood cells (the predominant source of 
maternal DNA in maternal plasma). However, up to now, known fetal epigenetic 
markers are relatively scarce for chromosome 13. Therefore, a systematic search on 
chromosome 13 for such marker was performed by methylated DNA 
immunoprecipitation coupled with tiling array analysis (MeDIP-chip), on placental 
and maternal blood cell genomic DNA. To implement the digestion-based detection 
method, I further searched for differentially methylated regions that overlap with 
multiple MSRE sites. To evaluate if the MeDIP-chip approach identified fetal 
epigenetic markers at a rate higher than by chance alone, I also performed a 
non-MeDIP-chip search, which randomly picked regions on chromosome 13, to 
ii 
search for markers. Subsequently, I further evaluated the MeDIP-chip-identified 
regions by two quantitative DNA methylation analytical platforms, namely the 
EpiTYPER (a mass spectrometry-based method), and bisulfite sequencing. 
After this systematic selection, I have identified a panel of potential fetal 
epigenetic markers. Among them, I selected the most promising marker and 
evaluated its detection and fetal specificity in maternal plasma. After that, I further 
evaluated the potential of this marker for the prenatal detection of trisomy 13 using � 
the EGG approach. By applying the chosen fetal epigenetic marker on chromosome 
13 and another fetal genetic marker {zinc finger protein, Y-linked, ZFY) in the EGG 
approach, I have demonstrated that it is feasible to distinguish trisomy 13 placental 
tissues from euploid ones. The EGG approach could potentially be extended to cover 
a larger population by using multiple paternally-inherited polymorphisms as the 
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SECTION I: BACKGROUND 
1 
Prenatal diagnosis of fetal aneuploidies 
CHAPTER 1: PRENATAL DIAGNOSIS OF 
FETAL ANEUPLOIDIES 
1.1 The need for prenatal screening and diagnosis 
Prenatal screening and diagnosis has become a standard obstetric practice in 
many countries nowadays. They are important for monitoring pregnancy. Moreover, 
parents could be informed earlier for further counceling about the choice of whether 
continuing a pregnancy or not, if the fetus has serious abnormalities, such as, fetal 
aneuploidies, the incidence of which being at least 1 in 25 in the population (Hassold 
& Jacobs，1984). 
1.2 Patau Syndrome (Trisomy 13) 
Patau syndrome, also known as trisomy 13 (T13), is a congenital disorder 
caused by the presence of an extra copy of chromosome 13 (Patau et a!., 1960). It is 
the third commonest fetal aneuploidies among livebirths with the incidence rate of 
around 1 in 20,000 (Hassold & Jacobs, 1984; Altug-Teber et al, 2007). Similar to 
other autosomal trisomies, the majority of trisomy 13 cases are thought to be 
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maternal in origin (Hall et al., 2007). It is speculated that the deterioration in the 
quality of the ova with advancing maternal age increases the risk of chromosomal 
abnormalities (Heffner, 2004). 
Moreover, fetal trisomy 13 is a common cause of reproductive failure in women 
of reproductive age. Fetuses with T13 were known to have high natural fetal loss rate 
of over 50% and about 80% of livebirths die within the first month (Iliopoulos et al, 
2006; Hall et al., 2007). Such low survival rate for trisomy 13 fetus may be caused 
by the abnormal dosage of genes located on chromosome 13. This could further lead 
to a downstream genome-wide transcriptional dysregulation of genes, which may 
disrupt important metabolic processes, including those coded by genes on other 
chromosomes (Altug-Teber et aL, 2007). The effect of an extra chromosome 13 has 
been found to be associated with several common phenotypic abnormalities, 
including severe growth and mental retardation, cleft lip and/or palate, skeletal 
abnormalities, central nervous system abnormalities, heart defects and hypotonia 
(Patau et al.，1960). These morphological malformations might be detected by 
sonographic examination (Chen, 2009). Given that the incidence of T13 decreases 
significantly across pregnancy (Hassold & Jacobs，1984)，detection of T13 could 
potentially be increased if screening was done earlier during pregnancy. 
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1.3 Current methods for fetal aneuploidy detection 
1.3.1 Routine prenatal screening tests 
Currently, prenatal screening programs are mostly developed for the detection 
of Down syndrome (trisomy 21, T21). Ultrasonography and maternal serum 
biochemical tests are two noninvasive methods commonly used for such screening. 
Ultrasonography is performed to assess the gestational age of the fetus, monitor 
fetal growth and visualize morphological defects, such as anomalies of the brain, 
kidney, heart and limbs. In the late first trimester, between 10-13 gestational weeks, 
an ultrasound nuchal translucency (NT) scan may be used to predict the risk of 
having chromosomal aneuploidy (Nicolaides et al., 1992a). The NT scan measures 
the amount of subcutaneous fluid at the back of the neck of the fetus. Fetuses 
affected by chromosomal aneuploidies tend to have subcutaneous accumulation of 
fluid, causing this clear space to be larger than average (Nicolaides et al., 1992b). 
For better risk assessment, ultrasound measurement of NT is usually coupled 
with serum biochemical screening tests. A number of maternal serum markers have 
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been identified for assessing the risk of Down syndrome pregnancies (Sailer & 
Canick, 2008). These markers were later found to be also useful for the detection of 
trisomy 13 (T13) and trisomy 18 (T18) pregnancies (Koster et al, 2010). Table LI 
summarizes all the current maternal serum markers in Down syndrome screening 
protocols with their respective test sensitivity and specificity. The risk of having a 
Down syndrome fetus is calculated, taking into account the maternal age and 
gestational age. Invasive procedures are performed to obtain the fetal genetic 
material for karyotyping for women with high risks of having T21 fetuses. 
Although fewer efforts have been paid into developing screening of T13 and 
T18 pregnancies, health care providers realize the potential role of using the existing 
first trimester screening protocol to detect T13 and T18 pregnancies (Tul et cd., 1999; 
Spencer et aL, 2000). By applying a new algorithm to calculate risks based on the 
first trimester combined test data for T21. screening, one could also detect T13 and 
T18 at a sensitivity of 80% and 77%, respectively, and at a false-positive rate of 5% 
(Koster et aL, 2010). However, T18 cannot be fully distinguished from T13 using 
this algorithm. To further improve the test result, extra markers could be incorporated 
into the screening protocol. These markers include fetal heart rate (Kagan et aL, 
2008)， fetal nasal bone length (Kagan et al, 2009), characterization of 
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craniomaxillofacial malformations (Ettema et aL’ 2010) and first-trimester serum 
markers [such as A Disintegrin and Metalloprotease 12 (ADAM 12) (Laigaard et aL, 
2009; Poon et al., 2009; Wortelboer, 2009) and Placental Growth Factor (PIGF) 
(Zaragoza et al., 2009)]. Screening for T18 and T13 pregnancies would facilitate 
earlier termination of pregnancy, as well as the notification about the possibilities of 
the related maternal complications. This is especially important for T13 pregnancies, 
which were reported to have an increased risk to develop severe and early-onset 
preeclampsia (Boyd et al.，1987). 
Both ultrasonography and biochemical screening tests suffer from certain 
limitations. Strictly defined gestational age windows must be used for each specific 
test. Moreover, since these methods only target the epiphenomena associated with 
chromosomal aneuploidies, rather than the core molecular abnormalities, they have 
limited sensitivities and specificities (Lo & Chiu，2008). Therefore, definitive 
diagnostic tests, which involve invasive procedures in obtaining fetal genetic 
materials for assessment of the core molecular abnormalities, are required for women 
with high risk of carrying fetuses with chromosomal aneuploidies. 
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1.3.2 Definitive prenatal diagnosis by invasive procedures 
For definitive diagnosis, chorionic villus sampling (CVS) and amniocentesis are 
commonly used to sample fetal materials from pregnant women for examination. 
Both procedures involve the insertion of medical instruments under continuous 
ultrasound guidance, and therefore, are invasive in nature. The procedure-related 
miscarriage rate for both processes is around 0.5 - 1.0% (Wilson, 2000). Therefore, 
these methods are not provided routinely for all pregnant women, but only for 
women with high risks of carrying affected fetuses with chromosomal aneuploidies 
(Sailer & Canick，2008). 
CVS involves the removal of small fragment of chorionic villi. It is usually 
performed in the first trimester, but not earlier than the week of gestation. Overly 
early sampling is associated with severe- limb reduction defects of the fetus with 
incidence rate as high as 1-2% (Wilson, 2000). Moreover, false diagnosis may be 
resulted, due to confined placental mosaicism, in which aberrant cells in the placenta 
that do not represent the chromosome status of the fetus are sampled for karyotyping 
(Wapner, 2005). 
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It has been observed that many patients who are offered first-trimester 
diagnostic testing by CVS opt to wait for amniocentesis in the second trimester 
(Sailer & Canick, 2008). The recent studies have suggested that amniocentesis is 
safer than CVS, making the former to be more attractive to many patients (Nanal et 
a/., 2003; Tabor & Alfirevic, 2010). Amniocentesis involves collection of amniotic 
fluid which bathes the fetus in the uterus. It is usually performed in the second 
trimester, but not earlier than the 15出 week of gestation, since overly early 
performance has been shown to carry a significantly higher risk of fetal loss (Wilson, 
1998). Other procedure-related complications have also been reported, such as 
amniotic fluid leakage (Sundberg et a!., 1997) and congenital foot deformity of the 
fetus (Nikkila et al, 2002). 
Molecular analysis such as karyotyping is performed to directly assess the 
chromosomal status of the fetus. Fetal cells obtained from CVS or amniocentesis are 
cultured for around 2 weeks to obtain enough fetal materials for analysis. By full 
karyotyping, a range of numerical and structural chromosomal abnormalities could 
be identified, including trisomy, chromosome translocation, chromosome deletion 
and insertion. 
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Although a definitive diagnosis can be achieved by karyotyping, the cell 
culturing procedures take about two weeks or even longer, which could increase 
parental anxiety and delay follow-up procedures (e.g. termination of pregnancy). 
Thus, molecular methods that are faster than karyotyping have been developed to 
detect the common autosomal and sex chromosome aneuploidies. These molecular 
methods involve the use of either PCR on DNA extracted from amniotic fluid and 
chorionic villus samples (Cirigliano et al, 2004), or fluorescence in situ 
hybridization (FISH) on uncultured amniotic fluid or chorionic villus cells (Ward et 
fl/., 1993; Lewin et al, 2000). Both methods are quicker than full karyotyping, with 
reports issued within 24-48 hours upon receipt of the sample. However, these 
techniques could only detect the common aneuploidies, while chromosomal 
structural abnormalities, such as translocations and inversions, will not be detected. It 
has been reported by some groups that up to 15-30% of chromosome abnormalities 
detected by karyotyping would not be detected by PCR or FISH testing (Caine et al., 
2005). Therefore, these molecular methods cannot fully replace the conventional full 
karyotyping. However, with most of the chromosomal abnormalities undetected by 
PCR or FISH are non-pathogenic, it has been suggested that they could be introduced 
as a preliminary investigation to shorten the turnaround time for issuing test results 
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1.4 New approaches for noninvasive prenatal diagnosis 
1.4.1 Circulating fetal cells 
The presence of fetal cells in the maternal body was first documented by Georg 
Schmorl, when he discovered the presence of fetal-derived trophoblast sprouts in the 
lungs of women who died of eclampsia (Schmorl, 1893). The significance of this 
discovery had been reasserted in 1969, when Walknowska et al detected 
lymophocytes carrying a Y chromosome in the peripheral blood of pregnant women 
carrying male fetuses (Walknowska et al, 1969). The initial goal of prenatal 
diagnosis using fetal cells in maternal blood was the isolation of intact fetal cells, 
followed by FISH analysis using probes for chromosomes 13，18, 21, X and Y, to 
diagnose the common fetal aneuploidies. The exploration of the potential of 
application of circulating fetal cells in noninvasive prenatal diagnosis had been 
intensively researched (Bianchi et al., 1990; Samura et al, 2000; Smits et al, 2000). 
However, the application was hampered by the relatively rare existence of intact 
fetal nucleated cells in maternal blood samples, in the order of about one cell in each 
milliliter of maternal blood (Bianchi et al, 1997). Moreover, circulating fetal cells 
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could persist in maternal blood after delivery up to as long as 27 years postpartum 
(Bianchi et al., 1996). This implies that the persisting circulating fetal cells from the 
previous pregnancy may interfere with the diagnosis performed using maternal blood 
from the current pregnancy (Iyer et al, 2003). 
1.4.2 Cell-free fetal nucleic acids in maternal circulation 
The existence of extracellular nucleic acids in the circulation was first reported 
by Mandel and Metais in 1948 (Mandel & Metais，1948). However, their work had 
not attracted much attention until 1977，when Leon's group showed that cancer 
patients had much higher concentrations of circulating DNA than those with 
non-malignant diseases (Leon et al, 1977). In 1996，the detection of tumor-derived 
DNA in the plasma and serum of cancer patients were reported by other groups 
(Chen et al, 1996; Nawroz et al., 1996). Prompted by these studies, Lo et al. 
hypothesized that fetal DNA might also exist in maternal plasma and serum. This 
hypothesis was based on the similarities between a malignant tumor and the placenta, 
which was regarded as "pseudomalignant" (Strickland & Richards，1992). Using a 
Y-chromosome DNA sequence present in the male fetus as a fetal marker, Lo et al 
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successfully demonstrated the presence of fetal DNA in the plasma and serum of 
pregnant women in 1997 (Lo et al., 1997). This discovery has offered new 
opportunities for noninvasive prenatal diagnosis. 
Subsequently, studies have been carried out to characterize the nature of 
cell-free fetal DNA in maternal plasma. Circulating fetal DNA molecules are 
predominantly short, with 80% of them being less than 200 bp (Chan et al., 2004). 
They represent only a minor proportion of cell-free DNA in maternal plasma, 
contributing about 3-6% of the total plasma DNA (Lo et al, 1998b). Circulating fetal 
DNA could be detected as early as day 18 after embryo transfer by assisted 
reproduction (Guibert et al., 2003). As gestation progresses, the fetal DNA 
concentration would increase, from a mean of 25 genome-equivalents (GE) per mL 
in early pregnancy to 292 GE per mL in late pregnancy (Bianchi, 1998; Lo et al., 
1998b). Moreover, unlike fetal cells, fetal DNA is cleared extremely rapidly from the 
maternal plasma following delivery, with a mean half-life of 16.3 minutes (Lo et al, 
1999c). With the report of detection of fetal DNA in maternal urine, it was suggested 
that the renal system is one of the mechanisms for clearance of plasma DNA 
(Botezatu et al.，2000). The circulating fetal nucleic acid was thought to be 
predominantly originated from the placenta (Bianchi, 1998; Ng et al； 2003; Flori et 
13 
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fl/., 2004; Chim et al, 2005). One mechanism for fetal nucleic acid release into 
maternal circulation is via apoptosis (Tjoa et ah, 2006). 
The use of circulating cell-free fetal DNA in the development of noninvasive 
prenatal testing offers advantages over the use of circulating fetal cells. First, the 
high relative concentrations of cell-free fetal DNA in maternal plasma, which are at 
least 2 to 3 orders of magnitude higher than those of intact fetal cells in the cellular 
fraction of maternal blood. This requires less effort for any prior enrichment of the 
target fetal genetic material and would reduce the chance of false-negative results 
due to limited quantity of fetal genetic material present in the sample. Second, fetal 
DNA is rapidly cleared from maternal circulation after delivery. This ensures that the 
analysis of fetal DNA in the current pregnancy would not be complicated by fetal 
DNA persistence from previous pregnancies. 
1.4.3 Diagnostic applications of cell-free fetal nucleic acids in maternal plasma 
The discovery of circulating cell-free fetal DNA in maternal plasma has offered 
new opportunities for noninvasive prenatal diagnosis. These applications can be 
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divided into two main groups, namely, qualitative and quantitative assessment. 
Qualitative analysis allows either a positive identification of, or an exclusion of, 
a genetic trait or disease. It has been used for the noninvasive prenatal determination 
of fetal RhD status in RhD-negative women, who are at risk of rhesus D 
incompatibility (Lo et al., 1998a; Finning et cd., 2008); fetal sex determination in 
diseases such as hemophilia (Costa et al, 2002; Santacroce et al” 2006) ； congenital 
adrenal hyperplasia (Rijnders et al, 2001); and prenatal detection of paternally 
inherited mutations in single-gene disorders such as B-thalassemia (Chiu et al, 2002; 
Ding et al., 2004). Among these applications, fetal RhD blood group typing has been 
translated into clinical service in some European countries (Finning et al., 2004; 
Gautier et al, 2005; Roque, 2006). 
Quantitative assessment may allow noninvasive detection or monitoring of 
pregnancy-associated disorders that are associated with abnormal levels of 
circulating fetal DNA, such as pregnancies involving preeclampsia (Lo et aL, 1999b; 
Levine et al, 2004)，preterm labor (Leung et cd., 1998) and fetal chromosomal 
aneuploidies (Lo et al, 1999a; Lee et al, 2002). However, the accurate detection of 
aberrant concentrations of fetal DNA in maternal plasma is technically challenging 
15 
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due to the fact that fetal DNA co-exists with a high background of maternal DNA (Lo 
et al, 1998b). Therefore, several fetal DNA enrichment methods have been proposed. 
For example, fetal DNA was selectively enriched by size fractionation (Li et al., 
2005). However, the degree of enrichment achieved is only moderate, and the 
procedures are susceptible to contamination. On the other hand, fetal DNA 
enrichment has also been reported by suppressing the maternal DNA background 
using formaldehyde (Dhallan et al,，2004). However, the results of this study have 
not been reproduced by a number of groups (Chinnapapagari et al., 2005; Chung et 
a/., 2005). 
Apart from the limitation of the high maternal background, the quantitative 
studies of fetal DNA in maternal plasma rely heavily on the use of Y-chromosomal 
markers. This would limit the application to pregnancies bearing male fetuses. Other 
areas have been researched intensively to provide alternative options for the 
noninvasive prenatal diagnosis. Much attention is given to the epigenetic approach in 
this thesis. The discovery and applications of fetal epigenetic (DNA methylation) 
markers would be elaborated in the next chapter. 
16 
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CHAPTER 2: DEVELOPMENT OF FETAL EPIGENETIC 
MARKERS IN MATERNAL PLASMA 
2 J Limitation of fetal DNA markers 
The discovery of fetal DNA in maternal circulation has opened up new 
possibilities for noninvasive prenatal diagnosis (Lo et al, 1997). However, as 
described in Chapter 1.4.3, most of the early applications were developed based on 
the detection of paternally-inherited DNA sequences, which are genetically 
distinguishable from the DNA sequences of the mother. Applications based on 
detection of the Y-chromosome would limit the use of this plasma DNA technology 
only to 50% of pregnancies involving male fetuses. Alternative approaches are thus 
required for detecting fetal DNA in maternal plasma. Increasing knowledge in the 
field of epigenetics has provoked scientists to explore the possibilities of detection of 
fetal DNA in maternal circulation by the epigenetic approach. Such an approach is 
based on epigenetic (DNA methylation) differences between the fetal and maternal 
DNA in maternal plasma. 
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2.2 DNA methylation is an actively-researched area under the field of epigenetics 
Epigenetics refers to the heritable changes in gene expression that occur 
independent of changes in the primary DNA sequence. Most of these heritable 
changes are established during differentiation and are stably maintained through 
multiple cycles of cell division, enabling cells to have distinct identities while 
containing the same genetic information (Sharma et al, 2010). Epigenetic 
modifications include DNA methylation, post-translational histone modifications, 
chromatin remodeling and non-coding RNA-directed alterations. Among them, DNA 
methylation is one of the best-studied areas. 
DNA methylation usually involves the attachment of a methyl group to the 
cytosine ring to form 5-methylcytosine (Bird, 2002). Such process is mediated by a 
family of enzymes called DNA methyltransferases (DNMTs), which transfer the 
methyl group from the methyl donor S-adenosylmethionine (SAM) to the cytosine. 
The DNMT family is further divided into two general classes based on their substrate 
DNA: maintenance DNA methyltransferase and de novo DNA methyltransferases. 
DNMTl is the major maintenance DNA methyltransferase in somatic cells. It 
preferentially methylates hemimethylated DNA. After DNA replication, only the 
18 
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parent DNA strand contains methylation, but not for the daughter strand. The 
preferential methylation of this hemimethylated DNA into a flilly methylated status is 
critical for passing epigenetic information between cell generations (Bestor et al, 
1988). DNMT3A and DNMT3B are de novo DNA methyltransferases, which are 
essential for establishing new DNA methylation patterns during development (Okano 
et al., 1999). DNMT3L is closely related in sequence to DNMT3A and DNMT3B, 
but lacks the catalytic domain. It mediates de novo methylation by stimulating the 
catalytic activity of an isoform variant of DNMT3A (Hata et al, 2002; Suetake et al, 
2004). 
DNA methylation has been suggested to cause genomic instability since 
5-methylcytosine in the genome is prone to the spontaneous deamination to thymine 
(Gonzalgo & Jones, 1997). This suggestion may correspond to the phenomenon that 
cytosine-to-thymidine to be a common class of point mutations causing human 
genetic disorders (Cooper & Youssoufian, 1988), and cytosine/thymidine variation to 
be a common type of genetic polymorphism in human populations (Jiang & Zhao, 
2006). 
DNA methylation usually takes place at the cytosine bases in CpG dinucleotides 
-
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in the mammalian genome (Bird, 2002). CpG dinucleotides are not evenly distributed 
across the human genome, but instead, are concentrated in CpG islands, which are 
short DNA regions with high GC content and high density of CpG dinucleotides 
(Gardiner-Garden & F r o _ e r , 1987; Takai & Jones，2002). CpG islands are 
preferentially located at the 5' end of genes and occupy around 60% of human gene 
promoters (Wang & Leung, 2004). While most of the CpG sites in the genome are 
methylated, the majority of CpG islands remain immethylated during development 
and in differentiated tissues (Suzuki & Bird, 2008). However, some CpG 
island-embedded promoters become methylated during development (Bird, 2002). 
Moreover, tissue-specific CpG island methylation has been reported in a variety of 
somatic tissues, primarily at developmentally important genes (Illingworth et al, 
2008). Therefore, it has been proposed that DNA methylation at CpG islands could 
provide insights about mammalian development and cellular differentiation, as well 
as pathogenesis (Illingworth & Bird, 2009). 
< 
2,3 Genome-scale DNA methylation analysis brings new insight into epigenetics 
DNA methylation at the gene promoter has long been thought to facilitate 
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transcriptional silencing, by preventing the recruitment of regulatory protein to DNA 
(Herman & Baylin, 2003). However, hypermethylation at the promoter region is also 
present for some genes with a significant level of expression (Jones, 1999). The 
advancement in DNA methylation analysis has facilitated whole genome methylation 
studies (Weber et al., 2005; Ball et al., 2009; Rauch et al., 2009; Laurent et a/., 2010). 
The studies have revealed a more general picture of the biological role of DNA 
methylation. 
Methylated DNA enrichment methods, such as the immunoprecipitation by 
antibodies against the 5-methylcytocine (Weber et al, 2005), or enrichment by 
methyl-CpG-binding domain (MBD) proteins that specifically recognize methylated 
DNA (Rauch & Pfeifer, 2005), have emerged as a powerful method for studying 
DNA methylation. The enriched products are then analyzed by the subsequent 
microarrays on a genome-wide scale (Weber et al, 2005; Rauch et al., 2006; Rauch 
遘 
et al, 2009). Recently, DNA methylation analysis of the whole human and 
Arabidopsis genomes at single-base resolution have been shown to be achievable by 
massively parallel bisulfite sequencing (Cokus et al., 2008; Lister et al, 2008). 
These advanced high-resolution analytical tools have revealed that DNA 
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methylation in different regions of a gene may play different roles in regulating gene 
expression. Unmethylated promoters have been found in certain highly-expressed 
genes (Rauch et al, 2009). However, intragenic methylation has been found to 
correlate with increased, but not decreased, transcription (Ball et al, 2009; Rauch et 
al, 2009; Laurent et al., 2010). It is suggested that intragenic methylation may 
improve transcription efficiency by repressing antisense transcript expression, which 
usually downregulates the expression of sense transcripts (Suzuki & Bird, 2008). 
Within the gene body, exons have been generally found to be more highly methylated 
than introns, and sharp transitions of methylation occurs at the exon-intron 
boundaries (Laurent et aL, 2010). This suggests a role of differential methylation in 
the splicing of RNA transcripts. All these studies have demonstrated how genome 
scale DNA methylation studies have brought new insights into the role of DNA 
methylation in regulating gene expression. 
< 
2,4 The first demonstration of using an epigenetic method for detecting 
maternally-inherited fetal DNA in maternal plasma 
Detection of maternally-inherited fetal DNA in the maternal plasma was 
_ 
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technically challenging due to the fact that fetal DNA is present in an excess 
background of maternal DNA in the maternal plasma (Lo et al, 1998b). With the 
increasing interest in the study of DNA methylation, Poon et al. explored the 
possibility of distinguishing fetal and maternal DNA in maternal plasma based on 
epigenetic differences (Poon et al., 2002). 
In 2002, Poon et al first demonstrated the detection of maternally-inherited 
fetal DNA in maternal plasma based on an imprinted region between the insulin-like 
growth factor 2 (IGF2) and HI 9 genes. This region is methylated if inherited from 
the father and unmethylated if inherited from the mother (Poon et al., 2002). When a 
pregnant woman has inherited a copy of this imprinted region from her father, the 
imprinted region becomes methylated in the cells of the pregnant woman. Poon et al 
hypothesized that, when the pregnant woman passed this copy on to her fetus (i.e. it 
becomes unmethylated in the cells of the fetus), the methylation status of the fetal 
< 
and maternal DNA in maternal plasma should be distinguishable from one another 
(Poon et al，2002) This was the first demonstration of using an epigenetic approach 
to distinguish fetal and maternal DNA in maternal plasma. However, this approach 
relies on the prior knowledge of the fetal genotype at the SNP within the target 
region. Furthermore, it is only applicable to fetuses who are heterozygous at this SNP, 
— 
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and who inherit the target allele from the mother, whom in turn has inherited it from 
the maternal grandfather (Poon et al, 2002). 
2.5 The first universal marker for fetal DNA in maternal plasma 
In 2005, Chim et al reported the first universal fetal epigenetic marker in 
maternal plasma, the promoter of the serpin peptidase inhibitor, clade B (ovalbumin), 
member 5 (SERPINB5) gene (Chim et al, 2005). Since the placenta is the major 
source of fetal nucleic acids in maternal plasma (Ng et al, 2003), while the maternal 
hematopoietic cells are the major source of maternal DNA in maternal plasma (Lui et 
al., 2002), it was proposed that loci exhibiting differential DNA methylation patterns 
between the placenta and maternal blood cells might be useful in developing fetal 
epigenetic markers for detection in maternal plasma. Previously, SERPINB5 was 
4 
reported to be a tumor suppressor gene expressed in the placenta (Dokras et al., 
2002). Another study reported that the expression level of the SERPINB5 gene was 
inversely correlated to the DNA methylation of its promoter (Futscher et al, 2002). 
The SERPINB5 promoter has been found to be predominantly unmethylated in 
placental tissues and predominantly methylated in maternal blood cells (Chim et al.， 
— 
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2005). Such differential methylation profile has enabled the development of 
hypomethylated SERPINB5 as the first universal marker for circulating fetal DNA in 
maternal plasma, irrespective of the sex and polymorphisms of the fetus (Chim et al, 
2005). The authors have also demonstrated that it is feasible to use this marker to 
detect the elevated concentrations of circulating fetal DNA in preeclampsia (Chim et 
a/., 2005). 
2,6 Discovery of more fetal epigenetic markers 
2.6.1 Methylated fetal epigenetic markers are more desirable 
The detection of the hypomethylated SERPINB5 sequences relied on bisulfite 
treatment of the DNA (Frommer et al, 1992; Herman et al, 1996). This is a process 
where unmethylated cytosine would be converted into uracil, and methylated 
cytosine would remain unchanged. Upon bisulfite treatment, the epigenetic 
difference is converted into a DNA sequence difference between the methylated and 
unmethylated DNA for detection. This allows the fetal-specific epigenetic signature 
to be distinguished from the maternal one (Chim et al, 2005). However, bisulfite 
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conversion is known to destroy up to 95% of the template DNA (Gnmau et al., 2001). 
This is detrimental for the detection of circulating fetal DNA markers, the 
concentration of which is already limited in maternal plasma (Lo et al, 1998b). 
In this regard, detection methods that do not involve the use of bisulfite are 
highly desirable. For example, for markers that are methylated in the placenta and 
unmethylated in maternal blood cells, methylation-sensitive restriction enzymes 
could be used to remove unmethylated maternal sequences while leaving methylated 
fetal sequences for subsequent detection (Lo & Chiu, 2008). 
2.6.2 Discovery of hypermethylated fetal epigenetic markers by studying tumor 
suppressor genes 
Ras association domain family 1 A [MSSFIA) is a tumor suppressor gene (TSG) 
present on chromosome 3 (Dammann et al, 2000; Lerman & Minna, 2000). Gene ‘ 
promoter hypermethylation is one of the mechanisms associated with TSG silencing 
and the pathogenesis of malignancies (Herman & Baylin, 2003). With the insight that 
the placenta has been regarded as pseudomalignant (Strickland & Richards, 1992), it 
has been hypothesized that the placenta might share similarity with tumor cells in 
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terms of epigenetic regulation, such as the methylation pattern within the promoter 
region of TSGs. Chiu et al investigated the methylation status of the promoters of a 
number of TSGs in human placental tissues and identified the promoter of the 
RASSFIA gene to be hypermethylated in the placenta but hypomethylated in 
maternal blood cells (methylation pattern opposite to that of the SERPINB5 promoter) 
(Chiu et aL, 2007). 
The methylation pattern of the RASSFIA allows the detection of 
placental-derived hypermethylated RASSFIA in maternal plasma by an approach 
based on the use of methylation-sensitive restriction enzyme (MSRE) digestion 
(Chan et al, 2006). After the digestion by MSRE which remove the background 
immethylated RASSFIA maternal DNA, the methylated fetal RASSFIA DNA would 
remain intact for subsequent detection with real-time quantitative PCR (Chan et al., 
2006). By this approach, our group has successfully demonstrated that the 
€ 
hypermethylated RASSFIA could serve as a universal fetal marker in maternal 
plasma, regardless of fetal sex and genetic variations (Chan et al, 2006). Subsequent 
work has demonstrated that hypermethylated RASSFIA could also be used as to 
detect the elevated concentrations of circulating fetal DNA in preeclampsia, 
regardless of the fetal sex (Tsui et al, 2007). 
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2.6.3 Discovery of hypermethylated fetal epigenetic markers on chromosome 21 
In light of the development of hypomethylated SERPINB5 and hypermethylated 
RASSFIA as universal fetal epigenetic markers, scientists then attempted to search 
for fetal-specific epigenetic markers on chromosome 21, hoping to develop a 
noninvasive prenatal diagnostic test for fetal trisomy 21 (Chim et aL, 2008; Tong et 
al, 2010). A systematic search was performed for such markers on chromosome 21. 
Of the 114 studied genomic regions, 22 (19%) are differentially methylated between 
the maternal (blood cell) and fetal (placental) tissues (Chim et al, 2008). 
Another systematic screening was also performed to search for differentially 
methylated promoter regions on chromosome 21 and identified the putative promoter 
of holocarboxylase synthetase (HLCS) gene, which is hypermethylated in the 
placenta but hypomethylated in maternal blood cells (Tong et aL, 2010). Furthermore, 
the detection of trisomy 21 pregnancies using this marker by adopting a 
MSRE-based method and a chromosome dosage approach was also demonstrated in 
the same study (Tong et aL, 2010) (to be discussed in detail in Chapter 2.7.2). 
These studies have shown that differential DNA methylation patterns between 
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maternal and fetal DNA may be commonplace. Thus, a further systematic search, 
beyond the CpG islands or gene promoters and on other chromosomes, for such 
DNA methylation differences is warranted. 
2.7 Noninvasive detection offetal aneuploidies using fetal epigenetic markers 
2.7.1 Noninvasive detection of fetal trisomy 18 by the epigenetic allelic ratio 
(EAR) approach 
The discovery of fetal epigenetic markers on chromosomes which are involved 
in the fetal chromosomal aneuploidies allows the assessment of fetal trisomic status 
by analysis of fetal DNA in maternal plasma. Fetal trisomic status could be inferred 
by the extra dosages of fetal DNA originating from the target chromosome in 
maternal plasma. The discovery of the fetal-specific hypomethylated SERPINEB5 
gene, which is located on chromosome 18 (Chim et aL, 2005), offered opportunities 
to analyze fetal chromosome 18 in maternal plasma, and thus, for the detection of 
fetal trisomy 18 (Tong et al.，2006). Tong et al have identified a single nucleotide 
polymorphism (SNP) (an A/C variation) within the target region. They reasoned that 
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a normal heterozygous fetus would have the allelic ratio of 1 (with genotype of AC), 
while that a trisomy 18 fetus would have an allelic ratio of 2 (with genotype of AAC) 
or 0.5 (with genotype of ACC) (Tong et al, 2006). They used this approach, named 
the epigenetic allelic ratio (EAR) approach, to detect fetal trisomy 18 in maternal 
plasma (Tong et al, 2006). 
However, this approach has two main disadvantages. First, the analysis relies on 
the genetic polymorphism, hence it is applicable only to fetuses that are heterozygous 
for the particular SNR To broaden the population coverage, one would need to 
identify more of such methylation markers that overlap with a polymorphism. 
Second, the analysis requires bisulfite treatment of the maternal plasma DNA, which 
could result in up to 95% DNA degradation (Grunau et al, 2001). Since fetal DNA is 
already present as a minor proportion in maternal plasma DNA (Lo et al., 1998b), 
further degradation of it would affect the robustness of the test. 
< 
2.7.2 Noninvasive detection of fetal trisomy 21 by the epigenetic-genetic (EGG) 
approach 
To overcome the limitation of the EAR approach, another approach, namely the 
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epigenetic-genetic (EGG) chromosomal dosage analysis, has been developed. This 
EGG approach involves the detection of a fetal-specific epigenetic on the aneuploid 
chromosome and a fetal genetic marker on a reference chromosome (Tong et al, 
2010). 
Tong et al. have identified a fetal epigenetic marker on chromosome 21, namely 
the putative promoter of the holocarboxylase synthetase (HLCS), which is 
hypermethylated in the placenta while remains essentially unmethylated in maternal 
blood cells. This marker allows the implementation of the EGG concept in the 
detection of trisomy 21 pregnancies (Tong et al, 2010). Upon treatment of maternal 
plasma by an MSRE, the unmethylated maternal DNA would be removed, while the 
fetal hypermethylated DNA would remain intact for detection. By comparing the 
concentrations of the fetal epigenetic marker on chromosome 21 to a fetal genetic 
marker, such as the zinc finger protein J-linked (ZFY) gene on chromosome Y, the 
< 
relative dosage of fetal chromosome 21 could be inferred from maternal plasma. 
With this approach, Tong et al have successfully demonstrated the detection of 
trisomy 21 pregnancies in maternal plasma samples (Tong et al.’ 2010). 
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2,8 Aim of thesis 
Noninvasive detection of trisomy 21 and 18 has been reported recently (Tong et 
al, 2006; Tong et al, 2010), however, only very few studies have been carried out 
for trisomy 13，which is the third commonest fetal aneuplodies. In this thesis, I aim 
to extend the EGG approach to detect trisomy 13 pregnancies noninvasively. It 
requires a fetal-specific epigenetic marker on chromosome 13. Until now, there are 
only two relevant reports in the literature that have systematically compared the 
DNA methylation patterns between the placenta and maternal blood cells (Chu et al, 
2009; Papageorgiou et al, 2009). However, both pieces of work did not contain any 
quantitative DNA methylation data at the resolution of CpG sites. Furthermore, there 
are no data from these two studies and other studies in the literature to show that 
MeDIP-identified regions are detectable in maternal plasma. 
Therefore, in this thesis, I embarked on a systematic search for such a fetal 
epigenetic marker on chromosome 13. I adopted a technology, which coupled the 
immunoprecipitation of methylated DNA with tiling array analysis (MeDIP-chip) to 
perform a high-coverage screen on chromosome 13. To facilitate the digestion-based 
approach, only genomic regions identified by the MeDIP-chip screening that 
— 
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overlapped with the recognition sites of MSREs would be further investigated. A 
multi-stage validation process would be implemented in order to choose a most 
promising fetal epigenetic marker out from the pool of potential markers. Once a 
promising fetal marker was identified, its detection would be evaluated in maternal 
plasma and the feasibility of the EGG approach would be examined. 
邃 
— 
SECTION II: MATERIALS AND METHODS 
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CHAPTER 3: METHODS FOR QUANTITATIVE ANALYSIS OF 
DNA METHYLATION 
3.1 Subject recruitment and sample collection 
Women with singleton pregnancies and women bearing male fetus with trisomy 
13 were recruited from the Department of Obstetrics and Gynaecology, at the Prince 
of Wales Hospital, Hong Kong, or the Harris Birthright Research Centre for Fetal 
Medicine, at the King's College Hospital, London, UK. All cases were recruited with 
informed consent. The study was approved by the respective institutional review 
boards. 
Maternal peripheral blood and placental tissue samples were obtained from each 
subject. 12 mL of maternal . peripheral blood was collected in 
< 
ethylenediaminetetraacetic acid (EDTA) tubes, just before and at 24 hours after the 
delivery, respectively. They were stored at 4°C, and would be processed within 9 
hours of collection of the samples. First- and second-trimester placental tissues were 
obtained by CVS while the third-trimestrer placental tissues were obtained 
immediately after elective cesarean section. The placental tissues of trisomy 13 
_ — 
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pregnancies were obtained before termination of pregnancy (TOP). Placental tissues 
were rinsed with diethyl-pyrocarbonate (DEPC) (Sigma-Aldrich, St. Louis, 
MO)-treated water and stored at -80°C before DNA extraction. Fetal karyotypes were 
confirmed by full karyotyping. The samples being used for each part of the study in 
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3.2 Sample processing 
Maternal peripheral blood samples were centrifuged at 1,600 g for 10 min at 4°C 
(Centrifuge 581 OR, Eppendorf, Germany). The upper plasma portion was transferred 
into plain polypropylene tubes and recentrifuged at 16,000 g for 10 min at 4°C 
(Centrifuge 5415R, Eppendorf, Germany). The supernatant was then transferred to 
new plain polypropylene tubes and stored at -20°C until DNA extraction. From the 
first centrifugation, the middle layer of buffy coat, which mainly consisted of white 
blood cells and platelets, was transferred to plain polypropylene tubes and 
recentrifuged at 2,500 g for 5 min at room temperature (Microlitre Centrifuge Z233 
M-2, Hermle, Germany). The residual plasma was removed, and the maternal blood 
cells were stored at -20°C until DNA extraction. 
3.3 DNA extraction 
3.3.1 Placental tissues 
DNA from placental tissues was extracted by the QIAamp DNA Mini Kit 
Quantitative analysis of DNA methylation 
(Qiagen, Hilden, Germany), according to the manufacturer's tissue protocol. For 
each sample, small pieces of placental tissue or chorionic villi were lyzed with 20 joL 
of Qiagen proteinase K and 180 \LL of buffer ATL at 56�C overnight on a rotating 
platform. 200 |xL of buffer AL was then added to the lysate and incubated at 70°C for 
10 min. After the incubation, 200 |iL of cold absolute ethanol was added for DNA 
precipitation. The mixture was transferred to a QIAamp Mini Spin Column and 
centrifuged at 6,000 g for 1 min (Microlitre Centrifuge Z233 M-2, Hermle, 
Germany). The Mini Spin Column was then washed with 500 |xL of wash buffers, 
AWl and AW2, sequentially. DNA was eluted twice with 50 [LL of 
DNase/RNase-free water and stored at -20°C. 
3.3.2 Maternal blood cells 
DNA from maternal blood cells was extracted by the QIAamp DNA Blood Mini 
Kit (Qiagen), with double the volumes suggested by the manufacturer's body fluid 
protocol. For each sample, 400 gL of blood cells was added to 40 |iL of Qiagen 
Protease, followed by the addition of 400 ^L of buffer AL. The mixture was 
incubated at 56°C for 10 min. After the incubation, 400 [iL of cold absolute ethanol 
was added for DNA precipitation. The mixture was transferred to a QIAamp Mini 
39 
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Spin Column and centrifuged at 6，000g for 1 min (Microlitre Centrifuge Z233 M-2, 
Hermle, Germany). The Mini Spin Column was then washed with 500 jjL of wash 
buffers, AWl and AW2, sequentially. DNA was eluted twice with 50 |xL of 
DNase/RNase-free water and stored at -20°C. 
3.3.3 Maternal plasma 
DNA from maternal plasma was extracted by the QIAamp DSP DNA Blood 
Mini Kit (Qiagen). To obtain enough extracted plasma DNA, 800 jiL of plasma, 
instead of the recommended 200 jiL, was subjected to DNA extraction. 800 \iL of 
plasma was divided into two aliquots for efficient extraction. For each of the 400 jiL 
plasma aliquots, it was added to 40 jiL of Qiagen Protease, followed by addition of 
400 jxL of buffer AL. The mixture was incubated at 56°C for 10 min. After the 
incubation, 400 jiL of cold absolute ethanol was added for DNA precipitation. The 
mixture was transferred to a QIAamp Mini Spin Column and centrifuged at 6,000 g 
for 1 min (Microlitre Centrifuge Z233 M-2, Hermle, Germany). The Mini Spin 
Column was then washed with 500 |iL of wash buffers, AWl and AW2, sequentially. 
The extracted DNA was eluted with 50 jiL of DNase/RNase-free water and stored at 
‘ “ "“ 40 
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3,4 Methylated DNA immunoprecipitation and tiling array analysis (MeDIP-chip) 
3.4.1 Principles 
A DNA methylation profiling method using methylated-DNA 
immunoprecipitation coupled with microarray (MeDIP-chip) has allowed 
genome-wide or chromosome-wide DNA methylation studies (Weber et al., 2005). 
The principle of the MeDIP-chip analysis is illustrated in Fig. 3,1. Briefly, an 
antibody against 5-methylcytosine is used to precipitate and enrich for methylated 
DNA, which is then hybridized to a DNA microarray and mapped back to the human 
genome (Weber et al, 2005). In my studies, a whole-genome tiling array set was 
chosen for identifying the methylated DNA in an unbiased way. 
4? 
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Fig, 3,L Methylation analysis by MeDIP-chip. 
A genomic sequence with either methylated (T) or unmethylated CpG sites was first 
fragmented by sonication followed by denaturation into single-stranded DNA 
fragments of desired length. The DNA fragments were then incubated with an 
antibody that recognized 5-methylcytosine (5mC-Ab), so that the methylated DNA 
could be isolated by immunoprecipitation (IP). After labeling of the DNA fragments 
with fluorescent dyes, methylation levels were determined by hybridizing the 
enriched methylated DNA to a microarray chip. A no-IP (did not undergo 
immunoprecipitation) control was also included. The ratio of IP over input was 
calculated for each spot on the array and used as a measure of methylation. 
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3.4.2 DNA sample and array processing 
3.4.2.1 DNA preparation and target hybridization 
DNA samples extracted from 5 euploid placentas and 5 maternal blood cell 
samples of the first-trimester were subjected to sonication for DNA fragmentation, 
followed by immunoprecipitation by antibody against 5-methylcytosines on the 
methylated CpG sites (Methylated DNA IP-on-Chip/Tiling, GenPathway Inc., San 
Diego, CA). After amplification and labeling with fluorescence, the products derived 
from each samples were hybridized onto the GeneChip Human Tiling 2.0R Array Set 
(Affymetrix, Santa Clara, CA) and washed. 
The GeneChip Human Tiling 2.0R Array Set of seven arrays contains 
approximately 45 million unique oligonucleotide probes to interrogate the human 
genome. The oligonucleotide probes are synthesized in situ complementary to each 
corresponding sequences, which have been selected from the NCBI human genome 
assembly with repetitive elements removed by the RepeatMasker. Probes are tiled at 
an average resolution of 35 nucleotides, as measured from the central position of 
adjacent 25-mer oligos, leaving a gap of approximately 10 bp between probes. The 
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comprehensive coverage and high resolution features offered by this tiling array 
allows an unbiased identification of the captured methylated DNA. 
3.4.2.2 Data analysis 
Data were acquired as image from the target-hybridized microarray chips and 
was analyzed by a data analysis algorithm named Model-based Analysis of Tiling 
array (MAT). The MAT data-mining algorithm analyzed the data with a probe 
standardization procedure, to adjust for the probe sequence context and genome copy 
number, to reduce the background probe noise (Johnson et al, 2006; Johnson et al, 
2008). The algorithm compared the signals between a treatment and a control group, 
which were the placenta (n=5) and the maternal blood cells samples (n=5) in this 
study. The algorithm calculated p-values for each comparison to determine if there 
was significant difference between the signals of the two groups. 65 loci were 
identified on chromosome 13 to contain statistically significantly higher methylation 
levels in the placenta than in the maternal blood cells samples (MATp-value < 10"^ ). 
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3.5 DNA methylation analysis on randomly-chosen regions on chromosome 13 
In order to address the efficiency of the MeDIP-chip analysis in identifying 
potential markers, an independent search on chromosome 13 without MeDIP-chip 
was performed for comparison. Independent from the MeDIP-chip dataset, 
systematic search was performed on chromosome 13 for loci with at least 5 
methylation-sensitive restriction enzyme sites (BstUl with recognition sequence of 
CGCG) within 100 nucleotides. The loci identified would proceed for methylation 
profiling. The reason for targeting methylation-sensitive restriction enzyme sites was 
due to the previously established bisulfite-independent method for the detection of 
methylated DNA sequences in plasma (Chan et al, 2006). A short stretch of DNA 
was required because fetal DNA, which were generally shorter than 150 bp, would 
eventually be targeted for detection (Chan et al., 2004). 122 loci were identified on 
chromosome 13 to bear such pattern, and 30 of them were chosen for validation (to 
be discussed in detail in Chapter 3,7). 
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3,6 Bisulfite conversion 
3.6.1 Principles of bisulfite conversion 
Bisulfite conversion refers to the chemical modification process by sodium 
bisulfite, which deaminates the unmethylated cytosine residues to uracil while the 
methylated cytosine residues remain unchanged (Shapiro & Weisgras, 1970; Wang et 
al, 1980). Such a chemical process would convert the epigenetic differences into 
sequence differences, which would then be detected by a number of methods, such as 
bisulfite genomic sequencing (Frommer et al., 1992)，methylation-specific PCR 
(MSP) (Herman et al., 1996), MALDI-TOF mass spectrometry (Ehrich et al.’ 2005) 
and high-throughput sequencing (Cokus et al, 2008; Lister et al, 2008). 
3.6.2 Procedures for bisulfite conversion 
Extracted DNA was bisulfite-converted using the EZ DNA Methylation Kit 
(Zymo Research, Orange, CA) according to the manufacturer's protocol. For each 
placental tissue or maternal blood cell sample, 1 |ig of DNA was denatured with 5 ^ iL 
of M-Dilution buffer at 37°C for 15 min in a 50 |xL total reaction volume. 
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Freshly-prepared CT Conversion Reagent was then added to the denatured DNA and 
the mixture was incubated at 50°C for 16 hours in the dark. Before purification, the 
converted DNA was chilled on ice for 10 min with further addition of 400 i^L of 
M-Binding Buffer. The mixture was then loaded onto a Zymo-Spin I Column and 
centrifuged at 16,000 g for 30 s (Microlitre Centrifuge Z233 M-2, Hermle, Germany). 
The column was then washed with 200 jiL of M-Wash Buffer. The sample was later 
desulphonated by incubation with 200 [iL of M-Desulphonation Buffer at room 
temperature for 15 min. After that, the column was washed twice with 200 of 
M-Wash Buffer. The bisulfite-converted DNA was eventually eluted with 20 i^L of 
M-Elution Buffer and stored at -20°C. 
3.7 Quantitative analysis of DNA methylation 
3.7.1 Bisulfite PCR and genomic sequencing 
3.7.1.1 Primer design for bisulfite polymerase chain reaction (TCR� 
Despite its laborious and time-consuming nature, bisulfite genomic sequencing 
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has been regarded as the "gold standard" for DNA methylation analysis due to the 
achieved high resolution. After bisulfite conversion, all the unmethylated cytosine 
residues are deaminated to uracil residues, this causes the initially complementary 
DNA strands to become non-complementary. Therefore, PGR primers were designed 
to target only one of the two bisulfite-converted DNA strands, and at the same time, 
to avoid any CpG sites at the primer binding site in order to prevent biased 
amplification of either methylated or unmethylated molecules. Since the chemical 
process of bisulfite treatment would also inevitably lead to DNA degradation, the 
amplicon size was designed not to exceed 450 bp to ensure that the 
bisulfite-converted template DNA could be bound and amplified by the pair of 
primers (Grunau et al, 2001). 
To assist in primer design, an online program called the EpiDesigner 
(Sequenom, San Diego, CA) was used (http://www.epidesigner.com/index.html). 
Pairs of forward and reverse primers were suggested by the program. However, they 
were taken for reference only, if the CpG sites of interest were not included in the 
amplicon of the suggested primer pairs, manual design was required. 
To increase the success rate of amplification, the primers would be further 
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checked to ensure (1) the binding specificity to the converted genome; and (2) the 
compatibility of the melting temperatures of the primer pairs. First, the specificity 
was checked using an online program called BiSearch (Institute of Enzymology) 
(http://bisearch.enzim.hu/?m= genompsearch) (Tusnady et al, 2005). After inputting 
the forward and reverse primer sequences into the program, it would perform an in 
silico PCR on a bisulfite-converted genome to search for any possible PCR products. 
Not more than four mismatches of the primer sequences with the bisulfite-converted 
genome were allowed. After the specificity check, the primer melting temperature 
(Tm) was checked by an online program called OligoAnalyzer 3.1 (Integrated DNA 
Technologies) (http://www.idtdna.com/analyzer/Applications/01igoAnalyzer/Default.aspx). 
The forward and reverse primers were maintained at 60°C (± 2°C). DNA tags would 
be added to the primers so that the same primer pairs could be used in both the 
bisulfite sequencing and EpiTYPER assay (to be discussed in details in Chapter 
J. 7.2.2). 
3.7.1.2 Bisulfite PCR 
Bisulfite-converted DNA samples were amplified using the GeneAmp PCR 
Core Reagent Kit (Applied Biosystems, Foster City, CA). PCR was set up in a total 
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reaction volume of 50 |iL containing IX Buffer II, 1.5 mM MgCb, 200 |j,M dNTP 
mix (Promega, Madison, WI), 200 nM each of the forward and reverse primers 
(Integrated DNA Technologies, Coralville, lA), 2.5 U of AmpliTaq Gold and around 
100 ng of the bisulfite-converted DNA template (in 2 ^L of the conversion product). 
The PGR was initiated at 95°C for 10 min, followed by 40 cycles of denaturation at 
95°C for 40 sec, annealing at 60°C 士 2°C, depending on the Tm of the primer sets) for 
1 min and extension at 72°C for 40 sec, it was finally incubated at 72°C for 7 min. 
3.7.1.3 Cloning 
After PCR amplification of the region of interest, the product was TA-cloned 
into the pGEM-T Easy Vector for transformation into Escherichia coli strain JM109 
(Promega, Madison, WI), according to the manufacturer's instructions. First, the 
PCR product was ligated to the vector by incubating at 16�C overnight in a 10 |iL 
reaction mixture, containing IX Rapid Ligation Buffer, 50 ng of pGEM-T Easy 
Vector, 3 Weiss units of T4 DNA Ligase and 3 |iL of the PCR products. 
The ligation product was then transformed into the competent cells by adding 2 
^L of the ligated product to 30 |iL of the JM109 cells. The mixture was first chilled 
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on ice for 20 min, followed by heat-shock at 42°C for 45 s and subsequent chilling on 
ice for 2 min. Cells were recovered by adding 950 |jL of super optimal broth with 
catabolite repression (SOC) medium (Invitrogen, Carlsbad, CA) with further 
incubation at 37°C for 1.5 hr with shaking. The cells were than centrifugated at 1,000 
g for 10 min for pelleting the DNA and then resuspended in 100 [iL SOC medium, 
before plating onto a LB agar plate containing ampicillin, 
isopropyl-beta-D-thiogalactopyranoside (IPTG) and X-Gal. The plate was incubated 
at 3TC for 16 hours to allow the bacterial colonies to develop. 
Clones with successful transformation were selected based on the blue/white 
screening molecular technique. X-gal, which is a colorless modified galactose sugar, 
could be metabolized by B-galactosidase to form an insoluble blue product and acts 
as an indicator. IPTG functions as an inducer for the B-galactosidase activity. With 
the successful insertion of DNA intp the vector at the coding region of the 
B-galactosidase enzyme, the production of functional B-galactosidase would be 
disrupted, resulting in white colonies. However, if the transformation fails, functional 
B-galactosidase enzyme is produced to hydrolyze the colorless X-gal into its 
characteristic blue color in the colonies. Therefore, only white clones were picked, 
since they contained the insert of DNA sequence of interest. However, bacterial 
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colonies were generally white in color, a bacterial colony with no vector could also 
appear white. This was suppressed by the presence ampicilin in the LB agar plate. 
The presence of the ampicilin-resistant gene on the vector allows successfully 
transformed bacteria to survive in the presence of the antibiotics. 
3.7.1.4 Bisulfite genomic sequencing 
White clones were picked randomly and suspended in 10 |iL of distilled water at 
95°C for 3 min. Nested vector primers T7 (5,-ACTCACTATAG GGCGAATTGG-3，） 
and SP6 (5'-GACACTATAGAATACTCAAGCTATGC-3') (Integrated DNA 
Technologies, Coralville, lA) were used to perform colony PCR to amplify the 
cloned inserts. In a 25 ^L PCR, Ix Buffer II, 2 mM MgCh, 200 i^M dNTP mix 
(Promega, Madison, WI), 100 nM each of the forward and reverse primers 
(Integrated DNA Technologies, Coralville, lA) and 1 U of AmpliTaq Gold were 
added to 3 |xL of the bacterial suspension. The PCR was initiated at 95°C for 10 min, 
followed by denaturation at 95°C for 40 s, annealing at 60°C for 1 min, extension at 
71�C for 40 s for 30 cycles, and a final incubation at 72°C for 7 min. The presence of 
inserts was confirmed by agarose gel electrophoresis. 
Quantitative analysis of DNA methylation 
Cycling sequencing was performed using the BigDye version 1.1 kit (Applied 
Biosystems). In a 10 reaction, 2 |iL BigDye, 2 |iL dilution buffer and 100 nM 
nested SP6 primer were mixed with 1 \iL of the colony PGR product. The mixture 
underwent the thermal profile of 25 cycles of 96°C for 30 s, 50°C for 15 s, and 60°C 
for 4 min. After purification by ethanol precipitation, the sequencing product was 
denatured with 10 i^L of HiDi formamide (Applied Biosystems) at 95�C for 1 min. 
Samples were then analyzed an automated capillary DNA sequencer (ABI PRISM 
3100 Genetic Analyzer, Applied Biosystems). 
3.7.1.5 Data acquisition and interpretation 
Sequencing data acquired by the ABI PRISM 3100 Genetic Analyzer Data 
Collection Software vl.0.1 were analyzed and output from the Sequencing Analysis 
Software 3.7 (Applied Biosystems). The sequencing data were analyzed using the 
SeqScape Software v2.5 (Applied Biosystems). The completeness of bisulfite 
conversion was confirmed by the absence of non-CpG cytosines within the analyzed 
amplicons. The presence of cytosine or thymine at the CpG sites was scored as a 
methylated or unmethylated CpG site, respectively. For each of the samples, 8 clones 
were collected for the scoring to calculate the methylation index (MI) at each CpG 
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sites according the following equation: 
M 
Methylation Index (MI)= 
M + U 
where M and U represent the number of methylated and unmethylated cloned DNA 
molecules, respectively. 
3.7.2 EpiTYPER, a mass-spectrometry-based method 
3.7.2.1 Principles of matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) 
The MassARRAY EpiTYPER system (Sequenom, San Diego, CA) has been 
developed as a rapid and quantitative platform for DNA methylation analysis (Ehrich 
et al., 2005). This chip-based technology is advantageous over the conventional 
bisulfite sequencing as it allows analysis of 384 samples within one or two days. 
The EpiTYPER DNA methylation analysis utilizes MALDI-TOF MS to analyze 
base-specific cleavage and amplification products. The base-specifically cleaved 
DNA products are dispensed by the MassARRAY Nanodispenser (Sequenom, San 
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Diego, CA), which dispenses 10-15 nL of EpiTYPER reaction products onto the 
SpectroCHIP matrix spots, where the DNA molecules crystallize with the matrix. 
The SpectroCHIP is then subjected to the Mass ARRAY Analyzer Compact Mass 
Spectrometer (Sequenom, San Diego, CA), which is a MALDI-TOF MS compact. 
The samples are first subjected to laser irradiation, leading to ionization of the 
biomolecules. With the matrix absorbing most of the laser energy, destruction of the 
DNA molecules is prevented. The ionized analytes are then accelerated towards the 
oppositely charged electric field and enter a vacuum flight tube. The time of flight of 
the DNA molecules were determined by the mass of each of the molecules reaching 
the detector. The larger the molecule, the longer the time of flight, and therefore a 
larger mass-to-charge ratio will be measured. The MassARRAY Analyzer Compact 
Mass Spectrometer provides a sensitive platform for distinguishing single-nucleotide 
difference between bisulfite-converted methylated and unmethylated DNA 
fragments. 
3.7.2.2 Primer design of the EpiTYPER assay 
Regions of interest identified by the MeDIP-chip analysis were first studied by 
EpiTYPER assays. Primer designs of the EpiTYPER assays were aided by the online 
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program EpiDesigner (described in Chapter 3.7.1.1). After the primer design, DNA 
tags were added on both of the forward and reverse primers. At the 5, end of the 
reverse primer, a sequence complementary of the T7 promoter, as well as an 8 bp 
insert, (5 ‘ -cagtaatacgactcactatagggagaaggct-3 ‘) was added, to ensure a T7 promoter 
was incorporated into the PGR product for the in-vitro transcription, and the 8 bp 
insert was for preventing abortive cycling. At the 5' end of the forward primer, a 10 
bp tag (5'-aggaagagag-3') was added for equalizing the melting temperature between 
the forward and reverse primers. 
3.7.2.3 The EpiTYPER assay and its principle 
After the bisulfite treatment of the genomic DNA, the region of interest was 
PCR-amplified using the HotStarTaq DNA Polymerase kit (Qiagen, Hilden, 
Germany). PGR was set up in a total reaction volume of 5 \iL containing IX Hot Star 
Buffer, 200 |iM dNTP mix (Promega, Madison, WI), 200 nM each of the forward and 
reverse primers (Integrated DNA Technologies, Coralville, lA), 0.2 U of HotStarTaq 
and around 50 ng of the bisulfite-converted DNA template (in 1 |iL of the conversion 
product). The PGR was initiated at 94°C for 15 min, followed by 45 cycles of 
denaturation at 94°C for 20 s, annealing at 60°C (土 2°C, depending on the Tm of the 
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primer sets) for 30 s and extension at 72°C for 1 min, it was finally incubated at 72°C 
for 3 min. 
The rest of the EpiTYPER reactions were performed using the MassARRAY 
MassCLEAVE kit (Sequenom, San Diego, CA). After PCR amplification, any 
unincorporated dNTPs were dephosphorylated by addition of 2 jiL of Shrimp 
Alkaline Phosphatase (SAP) to the PCR mixtures with further incubation at 37°C for 
20 min. The enzyme was then heat-inactivated by incubating at 85°C for 5 min. 
Successful PCR amplification was confirmed by agarose gel electrophoresis after 
this cleaning reaction. 
The in vitro transcription of DNA into RNA was performed in parallel with the 
base-specifically cleaved of the RNA fragments. A reaction was set up in a total 
reaction volume of 7 |iL, containing 0.64X of T7 Polymerase Buffer, 0.24 i^L of T 
Cleavage Mix, 3.14 mM dithiothreitol (DTT), 22 U of T7 RNA and DNA 
polymerase, 0.45 }ig of RNase A and 2 i^L of the PCR/SAP reaction mixture. The 
whole reaction mixture was incubated at 37�C for 3 hrs. The principle of generation 
of the base-specifically cleaved DNA fragments is illustrated in Fig, 3,2. 
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After the formation of the RNA fragments, 20 \iL of DNase/RNase-free distilled 
water and 6 mg of clean resin (Sequenom) were added into each well. The plate was 
rotated for 30 min and spun down for 5 min at 3,200 g. Samples were then dispensed 
by the MassARRAY Nanodispenser (Sequenom) onto a SpectroCHIP bioarray 
(Sequenom), and was put into the MassARRAY Analyzer Compact Mass 
Spectrometer (Sequenom) for resolving the mass of the DNA fragments. The 
detectable mass range of the CpG-derived fragments (regarded as CpG units) was set 
as 1500-7000 Da. Spectra data were acquired by the software SpectroACQUIRE, 
and can be analyzed by using the MassARRAY EpiTYPER 1.0 Analyzer 
(Sequenom). Since the bisulfite-converted methylated or unmethylated molecules 
were base-specifically cleaved, the RNA fragments which were transcribed from 
methylated or unmethylated DNA templates differed with a guanine or adenine at the 
CpG site. Such single-nucleotide difference could be detected as a 16 Da mass shift 
in the mass spectra of the analytes {Fig. 3.2). 
i 
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Fig. 3.2. Principle of EpiTYPER reaction on the MALDI-TOF MS platform. 
(to be continued on the next page) 
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Fig, 3,2. Continued. 
A genomic sequence with either methylated (^) or unmethylated CpG sites is first 
bisulfite converted and PCR-amplified regardless of the methylation status as shown. 
After SAP treatment, RNA molecules are generated by in vitro transcription with the 
presence of the T7 promoter tag at the PGR DNA products. This allows the 
subsequent base-specific RNA cleavage (at the uracil residue) and generation of 
RNA fragments (CpG units). The mass difference of the methylated- and 
unmethylated-DNA-derived fragments is then resolved by MALDI-TOF MS. The 
mass of a guanine residue is 16 Da larger than that of an adenine residue. Hence, 
CpG unit that contained one methylated CpG site would produce a 16 Da-mass shift 
from the CpG unit that contains an unmethylated CpG site. For each sample, a 
methylation index or MI will be calculated for each CpG site by dividing the peak 
height derived from the methylated molecules (blue) by the sum of the peak heights 
of both the methylated and unmethylated (red) molecules. 
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3.8 Methylation-sensitive restriction enzyme (MSRE)-mediated real-time 
quantitative PCR (qPCR) 
MSRE is a type of enzyme that only cleaves immethylated DNA but not the 
methylated DNA at its recognition site. It could be utilized for the detection of 
hypermethylated fetal DNA among the background of hypomethylated maternal 
DNA in the maternal circulation. The maternal background would be digested, 
leaving the fetal hypermethylated DNA intact and thus detectable by subsequent 
quantitative PCR (qPCR) (Chan et cd., 2006). 
In the design of the MSRE-mediated qPCR assays, primer and probes were 
strategically positioned such that the immethylated CpG sites in the maternal DNA, 
but not the methylated CpG sites, would be specifically cleaved by the relevant 
restriction enzymes. Each qPCR assay, was designed to be have amplicon length < 
120 bp. Shorter amplicon length was required because circulating fetal DNA, which 
are generally shorter than 150 bp, would eventually be targeted for detection (Chan et 
al, 2004). Each qPCR assays included three or more MSRE sites to allow more 
complete digestion of the unwanted immethylated maternal background. The 
specificity of all the primers were analyzed by using the "UCSC In-Silico PCR" 
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database and the "BLAT" database against the hgl8 (March 2006 assembly) on the 
UCSC genome browser (http://www.genome.ucsc.edu). The primer and probe 
sequences for various qPCR assays used in this thesis were summarized in Table 3.2. 
The MSRE-mediated qPCR assays were tested with placental and maternal 
blood cell samples, as well as maternal plasma samples. For the tissue samples, 30 ng 
of DNA was extracted from the placentas or maternal blood cells. For maternal 
plasma, 35 \iL plasma DNA was extracted from 0.8 mL plasma and then digested 
with MSREs. 
In this thesis, several digestion protocols of MSREs were used for different 
assays, the protocol components are summarized in Table 3.2. According to the 
manufacturer's suggestion, the combined volume of all added enzymes do not exceed 
10% of the total reaction volume, since the enzyme contains >50% glycerol in the 
storage buffer, which may affect the cleavage efficiency or may cause star activity. 
The digestion was terminated by heat inactivation (Table 3.2). 50 |iL of mineral oil 
(Promega) was overlaid on top of the reaction mixture to prevent evaporation. 
After digestion of the unwanted maternal background, any digestion-resistant 
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DNA was detected by real-time qPCR. All the real-time qPCR assays in this thesis 
were performed on the ABI 7300 Real-time PCR System (Applied Biosystems). For 
each reaction, a total reaction volume of 50 }j.L was set up by including 5 \iL of DNA 
sample with IX Universal Master Mix, each of forward and reverse primers 
(Integrated DNA Technologies, Coralville, lA) and the probe (Applied Biosystems or 
Integrated DNA Technologies). All the samples were analyzed in duplicate (with the 
Ct difference among the duplicate not more than 1) and the average was reported in 
the results. The components and preparation of the mixtures in the assays involved in 
this thesis are summarized in Table 3.3. The qPCRs were initiated at 50°C for 2 min, 
followed by heat activation at 95°C for 10 min, then 45 cycles of 95°C for 15 s and 60 
°C for 1 min. No template controls (NTCs) were included to detect the presence of 
contamination. For absolute quantification, a calibration curve made up of serially 
diluted male blood cell DNA, ranging from 3 copies per reaction to 10,000 copies 
per reaction, was run in parallel and in duplicates with each analysis. The limit of 
detection (LOD) for the three assays was 3 copies per reaction, which was 
determined by achieving 100% positivity in 40 replicate qPCRs performed at the 
LOD concentration. A conversion factor of 6.6 pg of DNA per cell was used, for 
expression of results as copy numbers. 
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Table 3.2. Primer and probe sequences for the qPCR assays. 
. Primer or „ /，，‘ ” � Tm Amplicon 
Assays p.^^e Sequence (5，to 3，） （。C) size (bp) 
Forward GAAATAAACGCCGGAACATCTTG 60^ 6 
FFNR? 
rUTR Reverse TCTCACGGAACCGTAGACTAGGAA 60.1 103 
Probe ' [FAM]ACAGAGCAGGAAGCCGATGTGACTGC[BHQ-1] 69.3 
Forward CAGGCCCCCTCACTCCTTC ^ 
E�NB2 Reverse CCTTCAAAGGGCCTGCCTT 60.1 87 
Intron4 � , 
Probe " [FAM]CGCGTTCCCGAGCTGTTCTGTTCTG[BHQ-1] 70^ 
"Hydrolysis probes using FAM as the reporter. Probes with Black Hole Quencher-1 (BHQ-1) were 
from Integrated DNA Technologies. 
Table 3.3. Composition of the methylation-sensitive restriction enzymes and the 
respective thermal profiles in the digestion reaction. 
(A) EFNB2_3，UTR 
Reaction mixture compositions Thermal profile 
Components Volume for one Final T * T. 
(Fermentas Life Sciences) reaction (nL) concentration lemperature lime 
FastDigest Buffer (1 OX) 6.0 IX 3?C 2 hr 
FastDigest^cd (1 FDU/^ iL) 2.0 0.03 FDU/|iL 65�C 20 min 
FastDigest NlalW (1 FDU/^ iL) 2.0 0.03 FDU/^ iL 
FastDigest HpaU (1 FDU/|iL) 2.0 0.03 FDU/jiL 




Reaction mixture compositions Thermal profile 
Components Volume for one Final 
(New England Biolabs) reaction (nL) concentration Temperature Time 
Initial mixture: Initial mixture: 
Buffer 2 (lOX) 5.0 IX 37°C 2 hr 
Acil (10 U/^ iL) 2.0 0.29 \]/\iL 80°C_ 20 min 
Aval (10 U/^ iL) 1.0 0.14 U尔L Additicmdhnixture: 
HpymWl (5 U/mL) 2 . 0 0 . 1 4 U / ^ L 6 0 ° C 2 hr 
Bovine Serum Albumin 0,5 
(BSA)(100X) IX 
DNase/RNase free distilled water 4.5 -
DNA sample ^ -
Additional mixture: 
Buffer 2(1 OX) 2.0 IX 
BstUI (5 卿L ) 2.0 0.14U/|iL 
DNase/RNase free distilled water 16.0 
Total 70.0 -
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Table 3,4. Reaction compositions of the qPCR assays. 
(A) EFNB2_Intron4 
Components Volume for one reaction (jiL) Final concentration 
TaqMan Universal Master Mix (2X) 25.0 IX 
Forward primer (50 jiM) 0.3 300 nM 
Reverse primer (50 |LIM) 0.3 300 nM 
Probe (10 _ 0.5 100 nM 
DNase/RNase free distilled water 18.9 -
DNA sample 5.0 -
Total 50.0 
{B)EFNB2J'UTR 
Components Volume for one reaction (jiL) Final concentration 
TaqMan Universal Master Mix (2X) 25.0 IX 
Forward primer (50 |xM) 0.9 900 nM 
Reverse primer (50 |a.M) 0.9 900 nM 
Probe (10 _ 1.25 250 nM 
DNase/RNase free distilled water 16.95 -
DNA sample 5.0 -
Total 50.0 
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3.9 Digital PCR 
3.9.1 Principles of digital PCR 
In digital PCR analysis, the quantification of DNA molecules is done by directly 
counting the number of template molecules after diluting the sample into extremely 
low concentration of less than one template molecule per reaction compartment on 
average (Vogelstein & Kinzler, 1999). After distributing the DNA molecules into the 
reaction wells of a 3 84-well reaction plate, PCRs were set up to amplify the template 
molecules in individual reaction chambers. The presence of a template molecule in a 
well would result in a positive amplification signal (Vogelstein & Kinzler, 1999). 
Such an approach allows transformation of the exponential, analog nature of 
conventional PCR into a linear, digital signal that simply indicates whether 
amplification has occurred, or not. Quantification of template molecules would be 
achieved by directly counting of the number of positive reaction wells. Previous 
studies have demonstrated that digital PCR offers a high precision in the analysis of 
circulating fetal DNA in maternal plasma (Lun et al., 2008). In Chapter 5, I would 
describe the use of digital PCR for distinguishing slight chromosomal ratio 
difference between euploid and trisomy 13 samples. 
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All the digital PGR assays described in this thesis were performed with the 
384-well plate format on the ABI 7900 Real-time PGR System (Applied Biosystems). 
Placental DNA extracted from euploid and trisomy 13 subjects were first quantified 
by spectrophotometry (NanoDrop Technologies, Wilmington, DE) before digestion 
by the MSREs. The digested DNA samples were then serially diluted so that the final 
concentration for the digital PGR was less than 1 template molecule per reaction well. 
For each placenta samples, two monoplex reactions were performed by distributing 
the enzyme digested DNA into the first 192 reaction wells for scoring of any wells 
with positive signals for ephrine B2 (EFNB2_3 VTR) gene sequences, and another 
192 reaction wells for scoring of any wells with positive signals for zinc finger 
protein, Y-linked (ZFY) gene sequences. The concentrations of the reagents were 
same as those of the real-time qPCR assay, but the volumes of all components in the 
mixture were scaled down to a total volume of 5 |iL, which was the individual 
reaction volume in each well. The thermal profile of the two monoplex assays was 
the same as that of the real-time qPCR assay, except that the cycle number for the 
EFNB2—3 VTR assay was increased from 45 to 55. 
Quantitative analysis of DNA methylation 
3.9.2 Poisson distribution 
In digital PCR, the DNA molecules are diluted into less than one template 
molecule per reaction on average. The number of wells with positive signals 
corresponds to the number of template molecules in the input sample. However, the 
actual number of template molecules distributed to each reaction well followed the 
Poisson distribution. The Poisson equation is given as follows: 
m e 
where n is the number of template molecules per well, P(n) is the probability of n 
template molecules in a particular well, and m is the average number of template 
molecules in the digital PCR experiment. An individual reaction well could contain 
zero, one, or more template molecules. The expected proportion of wells with no 
template is given by P(0) = e . For example, at an average concentration of one 
template molecule per well, the expected proportion of wells with no template 
molecules is given by i.e., 0.37 (37%). The remaining 63% of wells will contain 
one or more template molecules (Lo et cd.’ 2007a). Therefore, whether the PCR run 
operates at a digital level or not can be confirmed by seeing if approximately 37% of 
wells show negative amplification. 
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After the digital PCR run, the numbers of wells positive for chromosome 13 
(chrl3) or the reference chromosome for each of the two assays were then 
independently scored. For each sample, the Poisson corrected numbers of chrl3 and 
reference chromosome molecules were calculated separately in two monoplex 
reactions. Then, the ratio of molecule numbers of chrl3:reference chromosome was 
calculated. 
3,10 Statistical analyses 
All the statistical analyses in this thesis were performed with SigmaStat 3.0 
Software (SPSS). Mann-Whitney Rank-Sum test was used to detect statistically 
significant difference between 2 groups of samples, while the Wilcoxon's Sign Rank 
test was used for comparing the sample group before and after certain treatment or 
physiological changes, e.g. before and after delivery of fetus. Kruskal-Wallis test was 
used to detect any statistically significant difference among groups of samples. A 
difference withp-value < 0.05 was considered statistically significant. 
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CHAPTER 4: SYSTEMATIC IDENTIFICATION OF POTENTIAL 
FETAL EPIGENETIC MARKERS BY MEDIP-CHIP ANALYSIS 
4.1 Systematic discovery of fetal epigenetic markers on chromosome 13 by 
MeDIP-chip analysis 
Fetal trisomy 13 is the third commonest fetal chromosomal aneuploidy in the 
world. Until now, although there are chromosome-scale studies on the DNA 
methylation of chromosome 13, there are no reports on the quantitative DNA 
methylation data at the resolution of individual CpG sites. Recently, a new approach 
called Epigenetic-Genetic (EGG) chromosome dosage analysis has been proposed 
for the noninvasive prenatal detection of fetal trisomy 21 in maternal plasma (Tong et 
al, 2010). This study has prompted me to extend the analysis to detect fetal trisomy 
13. The EGG approach requires a fetal epigenetic marker, which is methylated and 
located on chromosome 13. At the time of launching this project, the availability of 
such markers on chromosome 13 was relatively limited. Therefore, I started a 
systematic study to search for such markers on chromosome 13. 
The emergence of high-coverage DNA methylation profiling method, such as 
“ ‘ T\ 
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MeDIP-chip (Weber et al, 2005), facilitates the global profiling of DNA methylation 
levels. This chapter presents a systematic profiling of DNA methylation levels on 
chromosome 13 by MeDIP-chip analysis and validation of potential fetal epigenetic 
markers by other analytical platforms of high resolution. The arrangement of various 
analytical platforms at each of the two screening stages was to enable a 
high-coverage screening on the entire chromosome 13, and a rapid and yet 
high-resolution quantitative DNA methylation studies for the potential fetal markers. 
The MeDIP-chip platform, which provided a high-coverage analysis, was adopted at 
the initial stage to discover more potential fetal epigenetic markers which may be 
located on any regions on chromosome 13. The pool of the potential markers was 
then validated by high-resolution platforms, namely the mass-spectrometry based 
EpiTYPER platform, and cloning and bisulfite sequencing analysis. Multiple criteria 
were applied at each step to select the most promising fetal epigenetic markers for 
further analysis. Moreover, I evaluated the efficiency of the MeDIP-chip approach in 
discovering potential fetal epigenetic markers by comparing with another 
MeDIP-independent screening method. 
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4,2 Experimental design 
Previous findings have demonstrated that placental tissues and maternal blood 
cells are the predominant sources of fetal and maternal DNA, respectively, in 
maternal plasma (Lui et al, 2002; Chim et al., 2005). Moreover, our group has 
demonstrated that differential methylation patterns between these two tissues could 
be developed into useful fetal epigenetic markers for detecting fetal DNA in maternal 
plasma. Therefore, I investigated the methylation patterns of these two tissues on 
chromosome 13 by MeDIP-chip analysis (experimental details have been described 
in Chapter 3,4). The detection of methylated fetal epigenetic markers in maternal 
plasma could be aided by digestion with MSREs, which remove the unmethylated 
maternal DNA background. Therefore, among the DNA regions identified by the 
MeDIP-chip analysis, only those with MSRE sites would be considered for further 
investigation. . 
Moreover，I evaluated the efficiency of the MeDIP-chip approach by comparing 
the number of potential fetal epigenetic markers identified by this strategy with that 
identified by a non-MeDIP approach. This non-MeDIP approach was based on a 
bioinformatics search on chromosome 13 for loci with > 5 BstUl (a MSRE) sites 
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within 100 nucleotides. There were 122 such regions on chromosome 13 (details 
described in Chapter 5.5). I focused on 100-nucleotide long regions because fetal 
DNA molecules are generally shorter than 150 bp in maternal plasma (Chan et al, 
2004). 
I further analyzed the loci identified by each of these screening approaches to 
identify potential fetal epigenetic markers. Bisulfite sequencing of cloned 
bisulfite-PCR products has been regarded as the gold standard of DNA methylation 
analysis because it yields data at the resolution of single CpG sites (Frommer et al., 
1992). However, this technology was relatively tedious and time-consuming. 
Therefore, I adopted a high-throughput quantitative DNA methylation analytical 
platform, namely the EpiTYPER, to analyze the loci. The tedious procedures of 
bisulfite sequencing, which involves cloning, limits the throughput of the analysis, 
while the EpiTYPER assays allow handling of 384 samples at each PCR run (Ehrich 
et al., 2005). Moreover, the resolution of DNA methylation analysis by this platform 
was close to the level of single CpG sites, and was comparable to that of cloning and 
bisulfite sequencing. Therefore, the candidates identified by the MeDIP-chip analysis 
were first validated by the EpiTYPER platform (see Chapter 3J�2 for the 
experimental details). For more effective utilization of resources, 2 pairs of placenta 
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and maternal blood cells samples were included in the first stage. Based on the data 
obtained at the first stage, I applied a set of criteria to select potential loci for further 
validation. The purpose of the validation step with additional samples was to assess 
the inter-individual variations of the methylation level of the potential loci. 
At the second stage of the validation, I performed bisulfite sequencing on the 
short-listed loci to obtain higher resolution DNA methylation data at the resolution of 
single CpG sites (see Chapter 3.7.1 for the experimental details). Similarly, for the 
more effective use of resources, 3 pairs of placenta and maternal blood cells samples 
were included at the first attempt. Loci that fulfilled the further defined criteria 
would then be validated with an additional of 3 pairs of samples. 
Throughout the validation procedures, criteria were set to identify potential fetal 
epigenetic markers on chromosome 13 that were methylated in the placenta, but 
unmethylated in maternal blood cells. Such methylation patterns would allow a 
MSRE-mediated fetal DNA detection method that would obviate the use of bisulfite 
treatment of DNA (Chan et aL, 2006). 
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4,3 Results 
4.3.1 Identification of differentially methylated DNA regions by MeDIP-chip or 
non-MeDIP approaches followed by EpiTYPER analysis 
The systematic workflow of identification of fetal epigenetic markers and the 
respective progress at each stage were summarized in Fig. 4.1. Using the 
MeDIP-chip analysis, I studied the methylation levels in 5 placental tissue samples 
and 5 maternal blood cell samples collected in the first-trimester, and searched for 
differentially methylated regions between them. The MAT data-mining algorithm 
identified 65 loci with statistically significantly different DNA methylation levels 
between the placenta and maternal blood cells (MAT p-value < 10"^ ). With the 
non-MeDIP approach, 122 ^^rUI-enriched loci were identified. To systematically 
identify potential markers, I applied a two-stage selection strategy (Fig. 4A). 
Every locus was examined for regions possible for designing EpiTYPER assays. 
An EpiTYPER assay was considered as informative only if its PGR amplicon: 
(i) mapped uniquely to the bisulfite-converted reference human genome. Since 
unmethylated cytosine residues were converted into thymine during bisulfite 
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conversion, more repeats were expected in the bisulfite-converted genome, and may 
result in more non-specific, and hence undesirable, PCR products, 
(ii) resulted in CpG-containing cleavage products (CpG units) that were detectable 
(within 1000-7000 Da detectable mass range) and distinguishable by MALDI-TOF 
mass spectrometry. 
Informative EpiTYPER assays were applied to DNA extracted from 2 placental 
tissues and 2 maternal blood cells collected during the first-trimester. The 
methylation index (MI) was calculated for each CpG unit for each sample: 
M 
Methylation Index (MI)= 
M + U 
where M and U represent the peak heights derived from methylated and 
unmethylated molecules, respectively. For each CpG unit, the Mis from the two 
placentas were then averaged. Also, for each CpG unit, the Mis from the two 
maternal blood cell samples were averaged. 
A locus was considered usable for developing into a fetal epigenetic marker if 
any of its EpiTYPER assay contained > 3 CpG units fulfilling both criteria: 
(1) MI in maternal blood cells < 0.2, and; 
(2) MI in placenta > 0.5. 
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Eight MeDIP-identified loci were found to fulfill the above criteria {Fig, 4,2), but no 
non-MeDIP loci were found to fulfill these criteria {Appendix 1). 
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c h r l 3 — ^ - d i i • m • • • • m i M i • • _ j 
(with 395,000 CpG sites) 
Loci identified Loci identified 
by MeDIP-chip by BstUI-density search 
65 loci 122 loci 
(with 2,286 CpG sites) (with 4,694 CpG sites) 
； i 
Loci with > 1 informative Epityper assay designed 
I I 
30 loci 30 loci 
(with 1,223 CpG sites) (with 1,107 CpG sites) 
i I 
Usable loci for developing fetal DNA markers 
(2+2 Epityper) 
8 loci ^. 
(with 231 CpG sites) 以 
i 
Loci with low inter-individual variation of DNA methylation levels 
(5+5 Epityper) 
5 loci 
(with 120 CpG sites) 
i 
Loci with useful CpG sites in conincident with any MSRE sites 
^ (3+3 bisulfite sequencing) 
2 loci 
(with 35 CpG sites) 
i 
Loci with useful CpG sites of low inter-individual variation of DNA methylation level, 
and at the same time, overlapping with any MSRE sites 
(6+6 bisulfite sequencing) 
2 loci 
(with 22 CpG sites) 
i 
Detection of potential fetal epigenetic marker 
in clinical samples 
Fig. 4,1. Systematic workflow of the identification of fetal epigenetic markers. 
(to be continued on the next page) 
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Fig, 4.1. Continued. 
The MeDIP-chip and non-MeDIP [55?UI-density search, bioinformatics search for 
loci with BstVl (a MSRE) sites within 100 nucleotides] approaches were 
performed to search for differential methylated DNA regions on chromosome 13 for 
developing fetal epigenetic markers. The term "loci" represents the genomic regions 
identified by either approach. Loci identified to be useful were selected for further 
validation. The number of loci and the number of CpG sites within the loci are 
shown in italics. The digits preceding the analytical method represent the number of 
placentas and maternal blood cell samples subjected to the particular analysis. For 
example, "2+2 EpiTYPER" represents the EpiTYPER analysis using 2 placenta 
samples plus 2 maternal blood cell samples. 
To evaluate the effectiveness of the MeDIP-chip screening, the non-MeDIP search 
approach was performed in parallel. Loci identified by either approach were 
validated by quantitative DNA methylation analysis. Among the 30 loci identified by 
the MeDIP-chip approach, 8 loci were shown to fulfill the basic criteria for 
developing fetal DNA markers. However, among the 30 loci identified by the 
non-MeDIP approach, no loci were shown to fulfill such criteria. Two potential fetal 
epigenetic markers, which fulfilled further criteria, were evaluated in maternal 
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4.3.2 Confirmation of differential methylation patterns and exclusion of regions 
with high inter-individual variations by EpiTYPER analysis 
In this part of the study, I aimed to select the most promising regions for 
developing fetal epigenetic markers in maternal plasma. Only the loci with CpG units 
of low inter-individual variations in DNA methylation in the placenta were chosen, 
because previous fetal epigenetic markers that possess consistent DNA methylation 
patterns across the placental tissues in different individuals has shown that this was 
important for their detection in maternal plasma (Chan et al,, 2006; Chim et al, 2005; 
Chill etaL, 2007). 
In this regard, among the 8 useful loci identified, I analyzed their 
inter-individual by EpiTYPER analysis. Loci chosen with criteria (1) and (2) were 
further analyzed in five pairs of placentas and maternal blood cells. The variation of 
« 
the placental MI was assessed by calculating the coefficient of variation (CV): 
Standard deviation /mean. 
Among loci fulfilling criteria (1) and (2), only those with any of its EpiTYPER 
assay containing > 3 CpG units which also fulfill criterion (3) were selected for 
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further analysis: 
(3) CV of the placental MI < 0.2. 
The CV of placental Mis of the independent CpG units as determined by EpiTYPER 
assays were shown in Fig. 4.3. Five loci fulfilling criteria (l)-(3) were analyzed with 
bisulfite sequencing to confirm the methylation data. 
< 
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Fig. 4.3. Mis of independent CpG units and the respective CVs of placental MI 
analyzed by EpiTYPER. 
Bar graphs show the Mis of five first-trimester placenta and maternal blood cell samples 
determined by the EpiTYPER assays and the CVs of placental MI. Green bars just below the 
pink bar graphs indicate the CpG units that fulfill criterion (1): MI in maternal blood cells < 
0.2 (below the red dotted line in the upper panel). Green bars just below the blue bar graphs 
indicate the CpG units that fulfill criterion (2): MI in placentas > 0.5 (above the red dotted ‘ 
line in the middle panel). Green bars just below the deep blue bar graphs indicate the CpG 
units that fulfill criterion (3): CV of placenta MI < 0.2 (below the red dotted line in the lower 
panel). The x-axis shows the CpG units within each locus, sorted according to the 
chromosomal location from the p arm to the q arm on chromosome 13. The lowest green 
bars (thick) indicate the CpG units that fulfill criteria (1), (2) and (3). Asterisks indicate loci 
with > 3 CpG units fulfilling criteria (1), (2) and (3). 
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4.3.3 Confirmation of differential DNA methylation patterns with higher 
resolution by bisulfite sequencing 
To obtain DNA methylation data at the resolution of single CpG site for the 5 
loci chosen with criteria (1), (2) and (3), I performed cloning and bisulfite 
sequencing with 3 pairs of placenta and maternal blood cell samples and calculated 
the MI at each CpG site for each sample (described in detail in Chapter 3.7,1). Then, 
I selected loci with any of its bisulfite sequencing assay containing > 3 CpG sites 
that fulfill the previously defined criteria (1), (2) and(3) and further fulfilling criteria 
(4)-(5): 
(4) MI in maternal blood cells < 0.1, and; 
(5) overlapping with MSRE sites. 
For better utilization of resources, bisulfite sequencing analysis was first 
< 
performed with 3 pairs of placenta and maternal blood cell samples. Among the 5 
loci studied, 2 of them contained > 3 CpG sites fulfilling criteria (1)，（2)，（3)，（4) and 
(5). I further analyzed the individual variations of the methylation levels of these two 
loci in 6 pairs of placenta and maternal blood cell samples by bisulfite-sequencing 
(Fig. 4.4，Fig, 4.5，Fig, 4.6), The bisulfite sequencing results of the loci not chosen 
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for further development were shown in Appendix II. 
These two loci, namely MAT. 13.0023 and MAT. 13.0038，were found to be 
located at the 3, end and intron 4, respectively, of the ephrine B2 (EFNB2) gene. The 
process of the identification of these two potential fetal epigenetic markers is 
summarized in Fig. 4,4, and the bisulfite sequencing results are shown in Fig, 4.5 
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Fig. 4.4. Continued. 
Top panel The genomic locations of the two potential fetal epigenetic markers on 
the EFNB2 gene are shown. Exons that code for protein {tall bars), 5'- and 3，-
untranslated regions (UTRs) (short bars) and introns {lines) are shown from the 5' 
end to 3’ end of the EFNB2 mRNA transcript. 
Second panel. A graph of the MeDIP-chip signals against the genomic locations of 
the MeDIP-chip probe on chromosome 13 is shown. Each vertical bar represents a 
probe, and its height represents the relative DNA methylation level between the 
placenta and maternal blood cell samples. Horizontal lines with arrows at both ends 
indicate the positions of the EpiTYPER assays within the MeDIP-chip loci. 
Third panel Quantitiative DNA methylation data by the EpiTYPER are shown on a 
color scale (yellow for MI = 0.0, green for MI = 1.0). 
Fourth panel. The same region was subsequently also analyzed by bisulfite 
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Fig, 4.5. Continued. 
(如 be continued on the next page) 
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Fig. 4,5, Continued. 
The bisulfite sequencing data of the 3’-UTR of the EFNB2 gene, with the loci ID 
MAT. 13.0023, is shown. At the first stage, 3 pairs of first-trimester placenta and maternal 
blood cell samples were bisulfite-sequenced (A). If the criteria for further developments 
were met, bisulfite sequencing analysis would be performed on 3 more pairs of samples (B). 
For each CpG site, the average MI and the respective placental CV of the Mis are shown on 
each graph. Bar graphs show the average Mis or the CVs of the placental MI determined by 
the bisulfite sequencing assays. Green bars just below the first (pink) bar graphs from the 
top indicate the CpG sites that fulfill criterion (4): MI in maternal blood cells < 0.1 (below 
the red dotted line, and thus also fulfill criterion (1)). Green bars just below the second (blue) 
bar graphs from the top indicate the CpG sites that fulfill criterion (2): MI in placenta > 0.5 
(above the red dotted line). Green bars just below the third (deep blue) bar graphs from the 
top indicate the CpG sites that fulfill criterion (3): CV of placenta MI < 0.2 (below the red 
dotted line). The chromosomal location highlighted in yellow indicates the CpG sites that 
fulfill criterion (5): overlapping with any MSRE site at the CG site. The bottom thick green 
bars indicate the CpG sites that fulfill criteria (1)，(2), (3)，（4) and (5). Among the five loci 
bisulfite-sequenced with 3 pairs of samples, only these two regions contain > 3 CpG units 
fulfilling criteria (1), (2)，(3), (4) and (5), and therefore were bisulfite-sequenced with 3 more 
pairs of samples. The raw data of the bisulfite sequencing result with 6 pairs of samples are 
< 
shown in (C). The methylation status of each CpG sites is displayed as filled (methylated) or 
unfilled (unmethylated) circles. A row of circles depicts the methylation status in a single 
DNA molecule isolated by cloning. The MI is calculated for each CpG site for each sample. 
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Fig. 4.6. Continued. 
The bisulfite sequencing data of the intron 4 of the EFNB2 gene, with the loci ID 
MAT. 13.0038，is shown. At the first stage, 3 pairs of first-trimester placenta and maternal 
blood cell samples were bisulfite-sequenced (A). If the criteria for further developments 
were met, bisulfite sequencing analysis would be performed on 3 more pairs of samples (B). 
The raw data of the bisulfite sequencing result with 6 pairs of samples are shown in (C). The 
graphical presentation of this figure is the same as that shown in Fig. 4.5. 
( 
- ^ 
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4,4 Discussion 
In this chapter, I performed a systematic search to identify fetal epigenetic 
markers on chromosome 13. MeDIP-chip analysis was performed to analyze the 
entire chromosome 13, which spans about 113 million base pairs (bp) and represents 
between 3.5 to 4% of the whole genome. The tiling array used in the MeDIP-chip 
analysis featured a high resolution analysis (a 25-mer probe per 35 nucleotides on the 
non-repeating region) when compared with other microarray (Gitan et al., 2002; 
Jacinto et al, 2008). Among the 395,000 CpG sites on chromosome 13, only 2,286 
CpG sites were identified by the MeDIP-chip analysis as differentially methylated 
between the placenta and maternal blood cell DNA (MATp-value < 10"^ ). 
These MeDIP-identified differentially methylated DNA regions (loci) had a 
median length of 1,244 bp. Each locus contained multiple CpG sites. These regions 
were then further analyzed to quantify the absolute DNA methylation levels, which ‘ 
were required for the development of a fetal epigenetic marker. In particular, it is 
important to ensure that the maternal background DNA methylation signal is low, 
because maternal blood cells contribute the majority of the cell-free DNA in maternal 
plasma (Lui et aL, 2002; Ng et al, 2003). 
_ 
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In this regard, the MeDIP-chip identified DNA regions would need to be 
further interrogated by an analytical platform which provides quantitative DNA 
methylation levels at higher resolution. The EpiTYPER platform was chosen to be 
the initial validation platform, since it allows the rapid analysis of DNA methylation 
close to the resolution of single CpG sites. This allows the identification of the most 
useful CpG sites within the long MeDIP-identified loci. For example, in the loci 
MAT. 13.0038 {Fig 4.2), no differential methylation was observed in the first 33 out 
of the 40 CpG units within this region. Only 8 CpG units clustered at the end of this 
region met our selection criteria for further investigation. This example demonstrated 
that the higher resolution methylation data obtained with the EpiTYPER allowed us 
to identify the most useful CpG sites for developing fetal epigenetic markers. 
In this project, among the 30 MeDIP-chip loci that were analyzed by 
EpiTYPER, 8 loci (27%) were selected for developing fetal epigenetic markers. The 
markers have high DNA methylation levels in the placenta but low methylation ‘ 
levels in maternal blood cells (Fig. 4.2). In contrast, for the non-MeDIP 
bioinformatics approach, among the 30 loci identified, no loci (0%) could be selected 
for further development {Appendix I). These data have demonstrated that MeDIP did 
enhance the rate of identifying fetal epigenetic markers. 
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The current discovery rate of fetal epigenetic markers by the MeDIP-chip 
approach was 27%. In the current dataset, I had only evaluated a subset of potential 
MeDIP-identified loci, which yielded one or more informative EpiTYPER assays. 
Based on the current discovery rate, I estimated that 9 loci (34 other loci not yielding 
any informative EpiTYPER assay x 27%) might also be useful in the development of 
fetal epigenetic markers if further investigated by other means (e.g. quantitative 
methylation-specific PCR or bisulfite sequencing) (Chim et aL, 2005; Tong et al, 
2006). 
In this chapter, after the multiple-stage validation and analysis, 2 loci located at 
the 3，-UTR and the intron 4 of the EFNB2 gene were identified as the most 
promising fetal epigenetic markers on chromosome 13. In the next chapter, I would 
discuss the detection of these two fetal epigenetic markers in maternal plasma. I 
would also discuss how the potential markers identified could aid the detection of 
fetal trisomy 13. ‘ 
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CHAPTER 5: THE APPLICATION OF FETAL EPIGENETIC 
MARKER ON CHROMOSOME 13 
FOR DETECTION OF FETAL TRISOMY 13 
5,1 Identification of a fetal epigenetic marker on chromosome 13 for the detection 
of fetal trisomy 13 by the epigenetic-genetic (EGG) chromosome-dosage approach 
In the last chapter, I have identified a panel of novel fetal epigenetic markers on 
chromosome 13. These potential fetal epigenetic markers were confirmed by bisulfite 
sequencing to be predominately methylated in the placenta and predominately 
unmethylated in maternal blood cells, which are the major source of fetal and 
maternal DNA, respectively, in maternal plasma (Lui et aL, 2002; Chim et al, 2005). 
Such a methylation profile enables the development of fetal epigenetic markers that 
are detectable in maternal plasma via a digestion-based approach, which is 
independent of bisulfite conversion. MSREs, which cut unmethylated sequences but ‘ 
leave methylated sequences intact, allow the selective removal of the unmethylated 
maternal sequences in maternal plasma. Hence, the fetal-derived methylated 
sequence in maternal plasma could be further analyzed. 
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As mentioned in Chapter 2,7，fetal epigenetic markers have been applied in the 
noninvasive prenatal detection of two common fetal aneuploidies, namely trisomy 18 
(Tong et al., 2006) and trisomy 21 (Tong et aL, 2006). In 2006, by analyzing the 
allelic ratio of a fetal-specific epigenetic marker located on chromosome 18, the 
unmethylated SERPINB5, in maternal plasma, Tong et al. have noninvasively 
detected fetal trisomy 18 in fetuses who are heterozygous for this marker, the 
so-called epigenetic allelic ratio (EAR) approach (Tong et al., 2006). To develop a 
noninvasive test for other fetuses in the general population, the epigenetic-genetic 
(EGG) approach, which was also based on a fetal epigenetic marker, namely the 
methylated HLCS, which is located on chromosome 21 has been developed. By 
determining the ratio between this fetal epigenetic marker on chromosome 21 
relative to a fetal genetic marker on a reference chromosome, namely the ZFY gene 
in maternal plasma, Tong et al. have detected fetal trisomy 21 noninvasively (Tong et 
al. 2010). Since the fetal genetic marker in the EGG approach can be substituted by 
any of the many paternally-inherited polymorphisms located on a reference ‘ 
chromosome, this EGG approach is potentially applicable to all fetuses in the general 
population. 
Yet, since the EGG approach is to distinguish only a rather small difference 
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between trisomic pregnancies (-3:1) and euploid pregnancies (�2:1)，an analytical 
platform of high precision is required. Fetal epigenetic markers are detected in 
maternal plasma by two major methods. One method depends on sodium bisulfite, a 
chemical reagent which converts unmethylated cytosine into uracil while leaving 
methylated cytosine unchanged. However, bisulfite has been reported to degrade 
>90% of the DNA undergoing the conversion reaction (Gnmau et al. 2001). Thus, 
the precision of a bisulfite-dependent analytical platform for detecting fetal 
epigenetic markers is likely to be low. Alternatively, fetal epigenetic markers can also 
be detected without bisulfite. Instead, MSRE, which digests only unmethylated, but 
not methylated DNA molecules are used in this alternative method. Using this 
bisulfite-independent method to detect the fetal epigenetic marker, i.e. the 
digestion-resistant methylated HLCS sequences, in maternal plasma, Tong et al. have 
obtained an analytical precision that was high enough to distinguish the small 
differences between trisomy 21 and euploid pregnancies (Tong et al. 2010). Hence, a 
fetal epigenetic marker that is suitable for the EGG approach is required to be ‘ 
digestion-resistant in maternal plasma after MSRE digestion. Consequently, in this 
clinical application arm of my study, I pursued a fetal epigenetic marker that is 
methylated in the placenta, and is located on chromosome 13. 
Detection of fetal trisomy 13 by the Epigenetic-Genetic (EGG) approach 
Among the panel of potential fetal epigenetic markers identified by MeDIP, I 
chose two of them, namely the 3，-UTR and the intron 4 region of the EFNB2 gene on 
chromosome 13. These two markers are measured by MSRE-mediated qPCR assays. 
Both markers were shown to be predominantly methylated in the placenta and 
essentially unmethylated in maternal blood cells. In this chapter, I aimed to develop 
MSRE-mediated qPCR assays targeting these two markers, and determine their 
potential clinical promise. I investigated the detection rate of the methylated EFNB2 
DNA in maternal plasma. I also studied the fetal specificity of the digestion-resistant 
EFNB2 DNA by studying its postpartum clearance pattern and investigated the 
correlation, if any, between this epigenetic marker and a fetal genetic marker in 
maternal plasma. Finally, I aimed to evaluate the feasibility of adopting these 
markers to detect fetal trisomy 13 with the EGG approach. 
« 
5.2 Experimental design 
I have developed two MSRE-mediated qPCR assays, namely EFNB2—3 VTR 
and EFNB2—Intron4’ which flanked the differentially methylated CpG sites in the 
3’-UTR and intron 4 of the EFNB2 gene, respectively. 
_ 
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I evaluated the efficiency of the respective digestion protocols of each target 
using third-trimester placental tissues (n = 5) and maternal blood cell samples (n = 5). 
Digestion was performed with different combination of MSREs before the respective 
detection of the EFNB2_3，UTR and the EFNB2 Jntron 4 digestion-resistant DNA. 
The experimental details have been explained in Chapter 3.8. Since maternal blood 
cells were the predominant source of maternal DNA in maternal plasma, the 
digestion protocol with the lowest detectable level of digestion-resistant maternal 
blood cell DNA would represent the highest digestion efficiency and thus the marker 
would be chosen for downstream evaluation. 
Next, I evaluated the detection of the digestion-resistant EFNB2 sequences in 
maternal plasma. Since the placenta was the prominent source of fetal DNA in 
maternal plasma, it would be expected that the digestion-resistant EFNB2 sequences, 
which were shown to be detectable in the digested placenta DNA, would also be 
detectable in digested maternal plasma samples. I evaluated whether this fetal 
epigenetic marker would be feasible for the detection of fetal chromosome 13 in 
maternal plasma. Eighteen maternal plasma samples from all three trimesters of 
pregnancies involving fetuses of either sexes were subjected to MSRE digestion. 
Digestion-resistant EFNB2 sequences were then sought for in these samples. 
102 
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Besides, the fetal-specificity of the chosen digestion-resistant EFNB2 
sequences was studied by investigating its clearance pattern in 10 pairs of maternal 
plasma after delivery of the fetuses. If the digestion-resistant EFNB2 was found to be 
fetal-specific in maternal plasma, it would be expected that the marker sequences 
would be removed from the maternal circulation upon delivery of the fetuses. I also 
studied if there is any correlation between concentrations of the chosen fetal 
epigenetic marker and a fetal genetic marker {ZFY) in maternal plasma (n=12) of 
pregnancies bearing male fetuses. A statistically significant and positive correlation 
would indicate that the digestion-resistant epigenetic marker was likely derived from 
the same source as the fetal genetic marker. If the epigenetic marker was confirmed 
to be fetal-specific, the concentration variation of this marker would be used to infer 
the dosage of fetal chromosome 13 in maternal plasma. In trisomy 13 pregnancies, an 
additional dosage of fetal chromosome 13 DNA could therefore be measured in 
maternal plasma using this marker. 
< 
Before applying this fetal epigenetic marker in the detection of fetal trisomy 13, 
I evaluated the methylation status of this marker in euploid (n = 5) and trisomy 13 (n 
= 5 ) placental tissue samples. I hypothesized that if the methylation levels of the 
marker do not differ significantly between trisomy 13 and euploid pregnancies, the 
103 
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marker would be potentially useful as a quantitative marker to compare the dosage of 
fetal chromosome 13 between the two groups of samples. The experimental details 
have been discussed in Chapter 3,7,2. 
Finally, I evaluated the feasibility of applying this fetal epigenetic marker to 
detect fetal trisomy 13 by the EGG chromosome dosage approach. I compared the 
relative chromosome dosage of the chosen fetal-specific epigenetic marker on 
chromosome 13 and a fetal-specific genetic marker {ZFY) using MSRE-treated 
placental DNA samples from euploid and trisomy 13 pregnancies. The evaluation 
was first carried out on placenta samples. If the EGG approach could successfully 
differentiate the euploid and trisomy 13 placenta samples, such an analytical 
approach might also be feasible in differentiating the euploid and trisomy 13 
pregnancies in maternal plasma samples. 
< 
I have developed two digital PGR assays to measure the concentrations of the 
epigenetic and genetic markers, respectively. The digital PCR platform was chosen 
because it provided a high precision in measurement. This high precision achieved 
would enable the differentiation of the small difference in relative chromosome 
dosage between the euploid and trisomy 13 samples. The experimental details have 
‘ 104 
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been explained in Chapter 3.9. 
5,3 Results 
5.3.1 Optimization of the digestion protocol 
I have developed two real-time qPCR assays towards the EFNB2_3 ’UTR and 
EFNB2_Intron4. I strategically positioned the qPCR primers to flank the CpG sites 
that were the most differentially methylated between the placenta and maternal blood 
cells, and also shown to be overlapping with MSRE sites. I then evaluated the 
efficiency of the digestion protocol in removing unmethylated maternal blood cell 
DNA sequences by subjecting the template DNA to the qPCR assay with and without 
MSRE digestion. The no enzyme. controls had the same reaction mixture 
< 
composition as that of the digested sample, except that 50% glycerol was added 
instead of MSRE. They were performed in parallel with the digestion reaction of 
each sample to control for any potential PCR inhibitors in the buffer during the 
qPCR measurement. Percentage of digestion-resistant DNA was calculated for each 
sample in each of the assay with the following equation: 
Detection of fetal trisomy 13 bv the Episenetic-Genetic (EGG) approach 
copies of digestion-resistant DNA in the digested sample , ^^^ 
% of input DNA left = t : — : x 100% 
copies of DNA in the no enzyme control 
The data in Chapter 4 have shown that both regions on the EFNB2 gene were 
predominantly methylated in placental tissues, but essentially unmethylated in 
maternal blood cells. It was expected that the MSRE digestion would digest most of 
the unmethylated EFNB2 DNA molecules which were derived mainly from maternal 
blood cells. In contrast, as the EFNB2 DNA molecules derived from placental tissue 
were predominantly methylated, it was expected that most of them would remain 
intact and amplifiable by PCR after digestion. The results demonstrated that after 
digestion, > 60% of placental EFNB2J VTR and EFNB2Jntron4 DNA sequences 
were detectable by the qPCR assays. Meanwhile, in the maternal blood cells samples, 
only < 1% of the input DNA remained detectable after MSRE digestion (Fig 5.1). 
As mentioned earlier, the fractional concentration of fetal DNA in maternal 
plasma is relatively low. The presence of any digestion-resistant maternal DNA 
would interfere with the detection of the digestion-resistant fetal DNA. The removal 
of maternal background DNA is important for a more accurate detection of the 
chromosome dosage of fetal chromosome 13 in maternal plasma. In maternal blood 
cell DNA samples after MSRE digestion, the EFNB2J VTR DNA and 
_ 
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EFNB2Jntron4 DNA remained detectable at median percentages of 0.3% and 0.7%, 
respectively. The EFNB2_3 'UTR region, which was shown to undergo a more 
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5.3.2 Detection of digestion-resistant EFNB2一3，UTR molecules in maternal plasma 
I next tested if the placenta-derived EFNB2J VTR DNA molecules, which are 
methylated and digestion-resistant, would be detectable in maternal plasma. I tested the 
MSRE-digested plasma DNA samples from all three trimesters of pregnancies involving 
fetuses of either sexes {Fig 5.2). The median concentrations of digestion-resistant 
EFNB2 J 'UTR DNA were 52 copies per mL plasma [interquartile range (IQR), 31-72], 
53 copies per mL plasma (IQR, 30-81), and 266 copies per mL plasma (IQR, 210-393), 
for the first, second, and third trimesters, respectively. The concentrations of 
digestion-resistant EFNB2_3’UTR DNA were different in the three trimesters 
(Kruskal-Wallis test, p = 0.001). To test the groups which were statistically significantly 
different, I further conducted the posthoc Student-Newman-Keuls test. It was found that 
the concentrations of digestion-resistant EFNB2—3 ’UTR DNA in the third trimester of 
pregnancy were statistically significantly higher than those of the first and second 
trimester (Student-Newman-Keuls test, p < 0.05, for both comparisons). However, the 
concentrations between the first and second trimester did not show statistically 
significant difference (Student-Newman-Keuls test, p = 0.924). 
< 
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Fig 5.2. Box plots of digestion-resistant EFNB2_3*UTR DNA concentrations in 
first-, second-, and third-trimester maternal plasma. The line within each box 
donates the median. Limits of the box denote the and 75^ percentiles. Whiskers • 
denote the and percentiles. Filled circles depict the outliers. 
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5.3.3 Evaluation of the fetal specificity of digestion-resistant EFNB2_3，UTR DNA 
molecules in maternal plasma 
The fetal-specificity of digestion-resistant EFNB2J VTR DNA was first evaluated 
by the detection of the marker in 10 pairs of pre- and post-delivery samples of third 
trimester maternal plasma. I subjected the MSRE-digested plasma DNA to subsequent 
qPCR assays. The results showed that digestion-resistant EFNB2—3，UTR molecules 
were detectable in all pre-delivery maternal plasma samples. However, the concentration 
of the marker dropped significantly upon delivery (Wilcoxon signed-rank test, p = 0.002) 
(Fig. SJA). These results suggested that the digestion-resistant EFNB2J VTR DNA 
were largely cleared after delivery of the fetus, and thus showing a significant degree of 
fetal specificity. However, it is important to point out that the clearance was not 
complete for all 10 of the cases. This indicates that the fetal specificity is not absolute. 
Furthermore, as a control, the level of digestible EFNB2_3，UTR (mostly representing 
maternal DNA) was also measured in maternal plasma. The digestible EFNB2一3 'UTR 
did not change significantly before and after delivery (Wilcoxon signed-rank test, p = 
1.00) {Fig, 5.3B), showing that it was not fetal-specific. 
To further investigate the source of the digestion-resistant EFNB2_3 'UTR DNA in 
maternal plasma, I studied the correlation, if any, of the concentrations between the 
digestion-resistant EFNB2_3 'UTR DNA and ZFY, an established genetic marker for 
detecting fetal DNA in maternal plasma of pregnancies bearing male fetuses (Lun et al.’ 
2008). Both markers were quantified in the plasma of 12 pregnant women bearing male 
fetuses. Their plasma concentrations correlated significantly (Spearman correlation, r = 
^ 111 
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0.860, p < 0.00001) {Fig. 5.4). The results suggested that the digestion-resistant 
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Fig. 5.4, Correlation between the concentrations of digestion-resistant 
EFNB2一3，UTR and ZFF DNA in maternal plasma. 
Both markers were quantified in the MSRE-digested plasma DNA samples from 12 
< 
pregnant women bearing male fetuses. Since the ZFY target did not contain the 
recognition sites of any MSRE used in the digestion protocol, the detection of ZFY 
would not be affected by the digestion. 
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5.3.4 Comparison of EFNB2_3 'UTR methylation profiles between the euploid 
and trisomy 13 placental tissue samples 
To further assess whether EFNB2_3 VTR is a suitable fetal epigenetic marker 
for quantitative comparison of the concentrations of chromosome 13 in euploid and 
trisomy 13 pregnancies, I evaluated the methylation levels of this region in placental 
tissues obtained from euploid (n = 5) and trisomy 13 (n = 5) pregnancies. I reasoned 
that if the methylation level at a particular CpG unit did not change significantly in 
the presence of an extra chromosome 13 (i.e. in trisomy 13), that CpG unit could 
potentially be developed into an epigenetic marker to quantitatively compare the 
dosage of fetal chromosome 13 in euploid and T13 pregnancies. 
I performed EpiTYPER analysis and calculated the MI of each CpG unit within 
the target region according to previously described procedures. Significant difference 
< 
in the Mis of the two groups, if any, was assessed using the Mann-Whitney 
Rank-Sum Test. 
The results indicated that between euploid and trisomy 13 placental tissues, 
there were no statistically significant difference in the MI of the CpG units that 
‘ ‘ ns 
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overlapped with the MSRE recognition sites involved in the digestion protocol (Fig. 
5,5). The result indicated that there was no significant change of methylation level at 
the EFNB2_3 'UTR region in the presence of an extra chromosome 13 in the trisomy 
13 placental DNA. The results suggested that digestion-resistant EFNB2_S 'UTR 
sequence would be a suitable quantitative marker to compare the concentrations of 
fetal chromosome 13 between euploid and trisomy 13 pregnancies. 
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Ml at CpG unit 
#1 #2 #3 #4 #5 — —> 
MSRE sites | | 
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placental DNA — 
#5 
T13 placental DNA 
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Mann-Whitney Rank Sum Test ；o-value 0-421' 0.032* 0,222 1.000 0 .03^ | 
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Fig. 5.5. Comparison of DNA methylation levels of the EFNB2一3，UTR region 
between euploid and trisomy 13 placental tissue samples. The DNA methylation 
levels of the euploid and trisomy 13 (T13) placental tissue samples were studied by 
the EpiTYPER assay. The MI of each CpG unit was calculated for each sample. 
Among the 5 CpG units, only two of them possessed statistically different (marked 
« 
with “*，’）MI between euploid and T13 samples (Mann-Whitney Rank-Sum Test). 
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5.3.5 Chromosome dosage analysis by the EGG analysis using placental tissue 
samples 
The previously described Epigenetic-Genetic (EGG) chromosome dosage 
analysis involved a fetal epigenetic marker on the aneuploid chromosome and a fetal 
genetic marker on a reference chromosome (Tong et al, 2010). In this experiment, 
the fetal epigenetic marker on chromosome 13 {EFNB2_3 'UTR) and a reference 
genetic marker {ZFY) were compared for the relative chromosome dosage analysis. I 
developed two digital PCR assays to detect these two markers in euploid (n = 10) 
and trisomy 13 (n = 5) placental DNA samples from pregnancies involving male 
fetuses. 
The analysis of digital PCR involved multiple analyses on highly diluted 
samples. The number of starting template molecules is determined by the direct 
counting of PCR products and calculation by Poisson statistics. The detail of the 
principle has been described earlier in Chapter 3.9. 
Each placental DNA samples were subjected to enzyme digestion prior to digital 
PCR analysis. The same enzyme-digested placental DNA samples was subjected to 
“ m 
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the EFNB2—3 'UTR and ZFY assays, respectively, in two monoplex assays. As a 
trisomy 13 fetus contains an extra dosage of chromosome 13 than a euploid fetus, it 
was expected that the ratio of digestion-resistant EFNB2J 'UTR DNA to ZFY DNA 
would be higher among the trisomy 13 cases. 
The EGG ratio of digestion-resistant EFNB2—3 VTR DNA to ZFY DNA of each 
sample was determined by dividing the Poisson-corrected count of EFNB2—3 'UTR 
DNA with that of ZFY DNA obtained in each digital PCR run. The ratios were 
significantly different between the euploid and trisomy 13 samples (Mann-Whitney 
Rank-Sum test, p-value = 0.023). A reference interval, defined as the mean ratio of 
digestion-resistant EFNB2_3，UTR DNA to ZFY DNA 士 1.96 standard deviation, 
was calculated from the euploid samples as 1.40 - 2.10. All except one of the trisomy 
13 cases had a ratio higher than the upper reference limit (Fig, 5,6). 
< 
One of the T13 cases was falsely classified as euploid according to the defined 
reference interval {Fig. 5.6). The counts of digestion-resistant EFNB2_3 'UTR DNA 
of this case is relatively low compared to others. One possibility is that this case 
might have a relatively low methylation levels in the EFNB2 DNA in placental 
tissues, such that the proportion of digestion-resistant molecules left after digestion 
‘ “ 119 
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was less than that of the other trisomy 13 cases. Thus, I checked the methylation 
levels of this placental sample with the data that I had obtained by the EpiTYPER 
analysis (Fig. 5.5). The methylation level of this case (case #5 in Fig. 5.5) was 
comparable to those of the other cases. Therefore, the methylation level of this case 
was unlikely the main reason for the low counts of digestion-resistant 
EFNB2一3 VTR DNA molecules. On the other hand, since the reference interval was 
defined according to the data obtained with a limited number of euploid cases, it was 
possible that more accurate differentiation of the euploid and trisomy cases could be 
achieved by further refinement of the reference interval with a larger sample size. 
In this study, the detection of trisomy 13 was only performed in placental tissue 
samples, but not in maternal plasma. This is because, although the digestion-resistant 
EFNB2_3 'UTR DNA was demonstrated to have a significant degree of fetal 
specificity in maternal plasma {Fig, .5.3), further optimization is needed before it 
4 
could be applied to detect fetal trisomy 13 in maternal plasma. 
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Fig. 5,6 Comparison of chromosome dosage in DNA samples from euploid and 
trisomy 13 placental tissues. Shown are ratios of digestion-resistant EFNB2—3 'UTR 
to ZFY, The reference interval of the euploid placental tissues, calculated as mean 士 
1.96 standard deviation (1.40 - 2.10), is depicted by the dotted lines. 
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5,4 Discussion 
In this chapter, detection of fetal trisomy 13 was illustrated with the 
employment of a fetal epigenetic marker EFNB2_3 VTR, which was identified by a 
systematic search on the entire chromosome 13 by coupling the MeDIP-chip with the 
other two high resolution DNA methylation analysis methods, namely EpiTYPER 
and bisulfite sequencing. This piece of work had demonstrated the feasibility and 
effectiveness of this multi-stage screening process in the identification of a fetal 
epigenetic marker for detecting fetal trisomy 13. The fetal-specificity of this marker 
was also confirmed in maternal plasma. Recently, two studies relevant to the search 
of fetal epigenetic markers on chromosome 13 have been published (Chu et ai，2009; 
Papageorgiou et al., 2009). However, both studies have not addressed if their 
proposed markers are detectable and fetal-specific. Furthermore, they have not 
demonstrated any application of the proposed fetal markers in detecting fetal trisomy 
< 
13 on clinical samples. The paucity of data has been addressed by the data presented 
in this chapter. 
On top of the fetal epigenetic marker on chromosome 13 employed in the 
detection of fetal trisomy 13, a fetal genetic marker on a reference chromosome was 
m 
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chosen instead of another fetal epigenetic marker for the relative chromosome dosage 
analysis. This was because in the study by Tong et al., they demonstrated that the 
EGG approach can more readily distinguish fetal trisomy 21 than an approach based 
purely on epigenetic markers (which measured the ratio of a fetal epigenetic marker 
on chromosome 21 to another fetal epigenetic marker on a reference chromosome, 
e.g. the RASSFIA on chromosome 3) (Tong et al, 2010). The suboptimal 
performance of the later approach could be due to the variability in the level of DNA 
methylation of both of the fetal-derived DNA molecules. Therefore, in this study, I 
have chosen a fetal genetic marker, the ZFY gene on Y chromosome, as the 
fetal-specific genetic target. 
In this study, detection of fetal trisomy 13 by the EGG approach was only 
evaluated in the placental tissue samples, but not in maternal plasma samples. It is 
because, although the fetal epigenetic. maker EFNB2_3 ’ UTR has shown a significant 
( 
degree of fetal specificity in maternal plasma, this fetal specificity is not absolute. 
The detection of fetal trisomy 13 could only be achieved by detecting the small 
difference between euploid and aneuploid samples in the relative chromosome 
dosage of the fetal epigenetic marker relative to the fetal genetic marker. Therefore, 
even a small amount of non-fetal-specific sequences of the epigenetic marker may 
m 
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affect the calculation of the relative chromosome dosage, and thus affecting the 
accuracy of the test. Thus, further optimization would be required before this fetal 
epigenetic marker can be applied for detecting fetal trisomy 13 in maternal plasma by 
the EGG approach. 
The EGG approach could be extended to pregnancies bearing female fetuses by 
using a genetic reference other than a Y-specific locus, such as a paternally-inherited 
polymorphic allele that is only present in the fetal genome but not the maternal 
genome. Such polymorphism could be located in any region of the genome, as long 
as they are not located on the aneuploid chromosome. If more fetal-specific 
polymorphic alleles could be incorporated as the reference, the detection of fetal 
trisomy 13 could be extended to cover a large population. 
< 
‘ m 
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CHAPTER 6: CONCLUSION AND FUTURE PERSPECTIVES 
6.1 Development offetal epigenetic markers for noninvasive prenatal diagnosis 
Since 1997, the progress of development of noninvasive prenatal diagnostic 
methods has been accelerated by the unexpected finding of cell-free fetal DNA in 
maternal plasma (Lo et al” 1997). Extensive researches have been carried out to 
demonstrate the potential and feasibility of qualitative and quantitative assessment of 
the fetal nucleic acids in maternal circulation for clinical diagnostics {Chapter 1.4) 
(Wataganara & Bianchi, 2004; Wright & Chitty, 2009). However, during the initial 
stage of the development, many of the applications were based on the detection of 
paternally-inherited fetal DNA sequences, which could only be applied to a subset of 
population. In 2002, detection of maternally-inherited fetal DNA from the maternal 
plasma was demonstrated with an epigenetic approach, which opened up new 
opportunities for the development of noninvasive prenatal diagnosis (Poon et al, 
2002). Since then, a number of fetal epigenetic markers have been discovered, and 
some were shown to be universally applicable to essentially all pregnancies, 
regardless of the fetal sex or the polymorphic status {Chapter 2). With the discovery 
of fetal epigenetic markers on chromosome 21 and 18，noninvasive prenatal 
ne 
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detection of fetal trisomy 21 and 18 have been reported (Tong et al., 2006; Tong et 
al,, 2010). However, no report has been published for a fetal epigenetic marker on 
chromosome 13 that can be applied in the detection of fetal trisomy 13, which is the 
third commonest fetal aneuplodies in the world. In this thesis, I carried out a 
systematic search for such a marker on chromosome 13. 
6.2 Systematic identification of fetal epigenetic markers on chromosome 13 
In order to facilitate a systematic chromosome-wide search for a fetal epigenetic 
marker on chromosome 13, a high-coverage DNA methylation profiling method is 
required. In Chapter 4, MeDIP-chip was adopted to identify potential fetal epigenetic 
markers. Among the 395,000 CpG sites spanning across a length of 113 million bp 
on chromosome 13，2,286 CpG sites were identified by the MeDIP-chip analysis as 
having differential methylation pattern between the fetal and maternal DNA. These 
MeDIP-identified loci were further validated with another mass spectrometry-based 
validation method EpiTYPER, which features a rapid and quantitative analysis of 
DNA methylation at a resolution close to single CpG-site level (Ehrich et al., 2005). 
In the past, high resolution analysis of DNA methylation was mainly done with 
— m 
Conclusion and future perspectives 
bisulfite sequencing, which was however tedious and time-consuming. Therefore, a 
high-throughput and high-resolution validation method would increase the efficiency 
of the search for a fetal epigenetic marker. This was demonstrated by the 
identification of a panel of potential fetal epigenetic markers that are located 
throughout the whole chromosome 13, as described in Chapter 4. Without the global 
methylation profiling tool or the high-resolution and rapid analytic platform, such 
CpG-site resolution methylation data would take a long time to obtain. Moreover, 
multiple stages of selection using criteria of different stringencies were implemented 
in the identification of the potential fetal markers. This systematic screening 
approach has ensured a reasonable balance between the cost and efficiency in this 
project. 
Massively parallel sequencing technology has emerged recently (Margulies et 
al, 2005). By coupling either the methylated DNA enrichment method or bisulfite 
conversion of genomic DNA with the sequencing platform, genome-wide scale study 
at single-base-resolution could be carried out. This has led to the development of 
methods like MeDIP-seq (Down et al, 2008)， direct sequencing of cytosine 
methylome (MethylC-seq) (Lister et al, 2008), high-throughput sequencing of 
bisulfite-treated DNA (BS-seq) (Cokus et al.，2008) and reduced representation 
Conclusion and future perspectives 
bisulfite sequencing (RRBS) (Gu et al, 2010). It is envisioned that these new 
technologies would allow the search for disease-specific DNA methylation pattern in 
the human genome. 
6,3 Detection of fetal trisomy 13 by the epigenetic-genetic (EGG) relative 
chromosome dosage analysis 
In Chapter 5，the detection of fetal trisomy 13 was illustrated using a fetal 
epigenetic marker on chromosome 13，located at the 3’ UTR of the EFNB2 gene. 
Prior to this work, only two studies systematically compared the DNA methylation 
levels on chromosome 13 between the placenta and maternal blood cells (Chu et al., 
2009; Papageorgiou et al., 2009). However, both of the studies did not demonstrate 
whether the proposed markers could be detected in maternal plasma, nor did they 
demonstrate any clinical utility of the proposed fetal epigenetic markers. The work 
described in Chapter 5 was the first to illustrate the feasibility of the detection of 
fetal trisomy 13 with an epigenetic approach. 
The detection of the fetal trisomy 13 was performed with the EGG approach, 
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which compared the relative chromosome dosage of a fetal epigenetic marker on 
chromosome 13 relative to another fetal genetic marker on a reference chromosome. 
The EGG approach has the advantage over the allelic-ratio analysis approach (such 
as the RNA-SNP approach (Lo et al., 2007b) and the EAR approach (Tong et al, 
2006)) as the EGG approach does not require the fetal epigenetic and genetic marker 
(e.g. the SNP) to coexist in the same genomic region. Without limiting the 
application to fetuses that are heterozygous for the analyzed SNP, the detection of 
fetal aneuploidy status by the EGG approach could therefore allow a higher coverage 
of the general population. Although a male-specific genetic marker was used as a 
model in this study, the coverage of the EGG approach could be extended to cover 
pregnancies involving female fetuses by using one or more paternally-inherited 
polymorphic alleles that are only present in the fetal genome, but not in the maternal 
genome. Moreover, this approach utilized the MSREs to remove the unmethylated 
background, and avoiding bisulfite treatment of DNA, which would lead to massive 
< 
degradation of the input DNA (Grunau et al, 2001) 
In this study, the fetal epigenetic marker EFNB2 on chromosome 13 was 
employed in the application of the EGG approach to illustrate the feasibility of this 
strategy for the detection of fetal trisomy 13. The EFNB2 marker was shown to have 
m 
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a significant degree of fetal specificity, and could also be detectable in maternal 
plasma during all three trimesters, regardless of the fetal sex. However, the fetal 
specificity of this marker was not absolute, so that the application of this marker for 
detecting fetal trisomy 13 in maternal plasma would be a challenage. Therefore, it is 
envisioned that further optimization would be needed before the marker could be 
applied in the noninvasive detection of fetal trisomy 13 in maternal plasma. 
The application of the EGG approach requires the employment of a 
fetal-specific epigenetic marker on chromosome 13 with reference to another 
fetal-specific genetic marker on a non-trisomic chromosome. Both markers are short 
DNA sequences on the respective chromosome. It is possible that other chromosomal 
structural abnormalities, such as translocations, inversions and duplication beyond 
the marker region, would not be detected by this approach. Moreoever, the variable 
level of mosaicism, which is a condition that cells within the same person having 
« 
different genetic makeup, may affect the accuracy of the result. However, these 
pathological conditions are not commonly seen (Carothers et aL, 1999; Forrester & 
Merz，1999). 
m 
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6,4 Future perspectives 
The definitive diagnosis of fetal chromosomal aneuploidy via the analysis of 
fetal nucleic acids in maternal plasma has been challenging owing to the low 
fractional and absolute concentrations of fetal DNA in maternal plasma (Lo et al, 
1998b). Recently, Chiu et al and Fan et al have demonstrated the feasibility of 
noninvasive prenatal diagnosis of trisomy 21 by massively parallel sequencing of 
maternal plasma DNA (Chiu et al., 2008; Fan et al, 2008; Chiu et al, 2010). This 
sequencing-based method identifies the genomic representation of each chromosome 
of plasma DNA molecule, so that the extra dosage of the aneuploid chromosome 
released by the fetus in maternal plasma could be accurately measured. However, up 
to this stage, the sequencing-based method requires a high instrumental and 
operational cost, which may not be affordable in many clinical settings. Moreover, in 
terms of the turnaround time, which is an important factor in clinical practice, the 
EGG approach described in this study allows the analysis of a number of samples ‘ 
within one day. The turnaround time of the EGG approach is faster than the 
sequencing approach at this stage. Before the cost and the turnaround time of the 
sequencing platform decrease, noninvasive prenatal diagnostic tests based on fetal 
epigenetic markers or other fetal-specific target would be reasonable alternatives for 
— 
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safe prenatal diagnosis. However, as some rare chromosomal structural abnormalities 
may not be detected by the EGG approach, conventional karyotyping may be offered 
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Fig. L Mis of independent CpG units of loci identified by the MeDIP-chip approach (A) 
and the non-MeDIP-chip approach (B) that were not selected for further validation. 
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Fig. I. Continued. 
The graphical presentation of this figure is the same as that of the Fig. 4.2. For (A), the 
upper panel shows the information for the first 200 CpG units while the rest are shown in 
the lower panel. For (B), the upper panel shows the information for the first 300 CpG units 
while the rest are shown in the lower panel. 
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Appendix II: Bisulfite sequencing results of the loci not selected for further development 
Fig. II. Continued. 
The bisulfite sequencing results of the four loci: MAT. 13.0038 (Al), MAT.13.00014 (Bl), 
MAT. 13.0002 (CI) and MAT. 13.0020 (Dl) are shown. The methylation status of each CpG 
sites are displayed as a circle, with the filled and unfilled circles representing methylated and 
unmethylated CpG sites, respectively. A row of circles depicts the methylation status across 
the CpG sites in a single DNA molecule isolated by cloning. Mis are calculated for each 
CpG site for each sample. The columns highlighted in green indicate the CpG sites fulfilling 
all the criteria for further downstream analysis. The average Mis for each CpG sites of the 
placenta and maternal blood cells, as well as the placental CV of the Mis, are calculated, 
with the results of the respective loci shown in (A2, B2, C2 and D2). Bar graphs show 
average Mis or placental CV of the MI measured by the bisulfite sequencing assays. Green 
bars just below the first (pink) bar graphs from the top indicate the CpG sites that fulfill 
criterion (4): MI in maternal blood cells < 0.1 (below the red dotted line, and thus also fulfill 
criterion (1)). Green bars just below the second (blue) bar graphs from the top indicate the 
CpG sites that fulfill criterion (2): MI in placenta > 0.5 (above the red dotted line). Green 
bars just below the third (deep blue) bar graphs from the top indicate the CpG sites that 
fulfill criterion (3): CV of placenta MI < 0.2 (below the red dotted line). The CpG site 
number highlighted in yellow indicates the CpG sites that fulfill criterion (5): overlapping 
with any MSRE site at the CG site. The bottom thick green bars indicate the CpG sites that 
< 
fulfill criteria (1)，（2)，（3)，（4) and (5). Among these four regions, none of them contains > 3 
CpG units fulfilling all the criteria (1), (2), (3), (4) and (5)，and therefore were not selected 
for downstream development in this study. 
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